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ABSTRACT  
Adenoviral gene therapy is an experimental approach to cancer refractory to standard 
cancer therapies. Adenoviruses can be utilized as vectors to deliver therapeutic transgenes 
into cancer cells, while gene therapy with oncolytic adenoviruses exploits the lytic 
potential of viruses to kill tumor cells. Although adenoviruses demonstrate several 
advantages over other vectors - such as the unparalleled transduction efficacy and natural 
tropism to a wide range of tissues - the gene transfer efficacy to cancer cells has been 
limited, consequently restricting the therapeutic effect. There are, however, several 
approaches to circumvent this problem. 
We utilized different modified adenoviruses to obtain information on adenovirus tropism 
towards non-small cell lung cancer (NSCLC) cells. To enhance therapeutic outcome, 
oncolytic adenoviruses were evaluated. Further, to enhance gene delivery to tumors, we 
used mesenchymal stem cells (MSCs) as carriers. To improve adenovirus specificity, we 
investigated whether widely used cyclooxygenase 2 (Cox-2) promoter is induced by 
adenovirus infection in nontarget cells and whether selectivity can be retained by the 
3’untranslated region (UTR) AU-rich elements. In addition, we investigated whether 
switching adenovirus fiber can retain gene delivery in the presence of neutralizing 
antibodies. 
Our results show that adenoviruses, whose capsids were modified with arginine-glycine-
aspartatic acid (RGD-4C), the serotype 3 knob, or polylysins displayed enhanced gene 
transfer into NSCLC cell lines and fresh clinical specimens from patients. The therapeutic 
efficacy was further improved by using respective oncolytic adenoviruses with isogenic 
24bp deletion in the E1A gene. Cox-2 promoter was also shown to be induced in normal 
and tumor cells following adenovirus infection, but utilization of 3’UTR elements can 
increase the tumor specificity of the promoter. Further, the results suggested that use of 
MSCs could enhance the bioavailability and delivery of adenoviruses into human tumors, 
although cells had no tumor tropism per se. Finally, we demonstrated that changing 
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adenovirus fiber can allow virus to escape from existing neutralizing antibodies when 
delivered systemically. 
In conclusion, these results reveal that adenovirus gene transfer and specificity can be 
increased by using modified adenoviruses and MSCs as carriers, and fiber modifications 
simultaneously decrease the effect of neutralizing antibodies. This promising data suggest 
that these approaches could translate into clinical testing in patients with NSCLC 
refractory to current modalities. 
15 
 
1 Introduction 
Lung cancer is one of the most common cancers and the leading cause of cancer-related 
mortality worldwide. It can be divided into two types: small-cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). Non-small cell lung cancer can be subdivided further 
into squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma and it accounts 
for approximately 80% of all lung cancers. A paucity of effective treatments exists for 
NSCLC patients. Treatments include chemotherapy and surgery, but in most cases the 
cancer is at advanced stage when it is detected and these treatments are not curative. 
Consequently, there is a need for new therapies (Ramalingam and Belani 2008).  
A promising treatment alternative for many types of cancers refractory to current 
modalities is adenoviral gene therapy. Adenoviruses are excellent vectors for gene therapy 
since they can infect many types of cells, can be grown to high titers, do not integrate into 
host genome, and, above all, they have low pathogenicity for humans (Glasgow et al. 
2004). Importantly, there are encouraging results in recent randomized trials concerning 
glioma, prostate, hepatocellular, and head and neck cancers (Immonen et al. 2004; Li et al. 
2007; Shirakawa et al. 2007). However, three potential limitations may have an impact on 
the efficacy of adenoviruses: 1) Adenoviruses do not transduce efficiently clinically 
relevant cancer cells, since they exhibit variable expression of adenovirus primary receptor 
coxsackie adenovirus receptor (CAR), 2) Adenoviruses do not have a natural preference to 
replicate only in tumor cells, 3) Replication may also be inefficient in large tumor masses, 
which are very complex in structure, and 4) Adenoviruses have a strong immunogenicity 
that especially affects systemic re-administration of viruses. 
To circumvent some of these problems, adenoviruses can be retargeted to cancer cells by 
improving their abilities to attach to heterologous receptors other than CAR, which can 
enhance gene transfer to the desired tissues (Bauerschmitz et al. 2002). Further, adenovirus 
replication can be controlled at transcriptional level by specifically engineered deletions in 
viral genes or tissue-specific promoters controlling crucial replication regulations, such as 
E1A, resulting in viruses that replicate only in cells where promoters are expressed 
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(Saukkonen and Hemminki 2004). Replication can also be controlled via 
posttranscriptional regulation with elements affecting replication at the mRNA level 
(Ahmed et al. 2003; Gahery-Segard et al. 1998). To avoid neutralizing antibodies (NAbs) 
raised by adenoviruses upon re-exposure, different serotypes of adenoviruses can be used, 
(Hashimoto et al. 2005), alternatively, even small changes in the Ad5 fiber knob can allow 
the virus to escape from pre-existing capsid-specific NAb (Gahery-Segard et al. 1998; 
Rahman et al. 2001). Further, using carriers such as mesenchymal stem cells (MSCs), 
which are not recognized by NAbs, can enhance gene transfer and antitumor efficacy 
(Studeny et al. 2004).  
We used capsid-modified adenoviruses to determine the adenovirus tropism towards 
NSCLC. In addition, we tested whether adenoviruses could be further targeted by 
regulating gene expression posttranscriptionally. Also, we present some unpublished data 
suggesting that although gene expression can be beneficially modulated with post-
transcriptional control elements in the context of plasmids, the effect was not powerful 
enough to be useful in the context of recombinant adenoviruses. We also studied the 
possibility of utilizing MSCs as carriers for oncolytic adenoviruses, thereby combining 
MSCs with the anti-tumor effect provided by oncolytic adenoviruses. Finally, we 
investigated whether the changing adenovirus fiber can retain gene transfer efficiency in 
the presence of adenovirus neutralizing antibodies. 
2 Lung cancer 
Lung cancer is the second (among men) and fourth (among women) most common cancer 
in Finland, with 2140 new cases in 2006 (Finnish Cancer Registry; www. 
cancerregistry.fi). The most common histological type of NSCLC is adenocarcinoma, 
followed by squamous-cell carcinoma and large-cell carcinoma. The prognosis of NSCLC 
is poor because the disease is often at an advanced stage when detected. The overall 5-year 
survival rate is only 8% for men and 12% for women. 
Treatment of NSCLC remains a challenge. Surgical resection at on early stage represents 
the only treatment associated with a high likelihood of attaining 5-year survival. However, 
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since the NSCLC is often detected at a later stage, combination therapies with radio- and 
chemotherapy are used. 
2.1 Molecular mechanism of NSCLC  
 Development of cancer, including NSCLC, involves accumulation of multiple molecular 
abnormalities over a long period of time. These include chromosomal abnormalities, 
inactivation of tumor suppressor genes, activation of oncogenes, expression of hormone 
receptors and, production of growth factors. The most common genetic alterations involve 
mutations in the p53/p14ARF, p16/retinoblastoma (Rb) and in K-ras pathways. These 
mutations involving tumor suppressor genes may be a rate-limiting event in the 
development of cancer (Brambilla et al. 1999).  
2.1.1 Tumor suppressors 
p53 is a tumor suppressor gene that is mutated in 2/3 human lung cancers, and it is 
commonly seen in squamous cell carcinomas. In normal cells, when DNA damage occurs, 
p53 can halt the cell cycle at the G1 checkpoint, preventing the cycle from proceeding to 
the S phase until the DNA is repaired or it can induce the cell to apoptosis. In cancer cells, 
by contrast, when p53 is mutated, the control is lost. The p16/Rb pathway regulates entry 
and progression through the cell cycle. Disruption in one or more factors in this pathway 
can lead to tumor genesis. p16 and pRb proteins are critical members of the Rb pathway, 
and they are mutated in 80% of NSCLC (Belinsky et al. 1998; Tanaka et al. 1998). In 
normal cells, when cell cycle protein p16 is needed, it functions as an inhibitor of the 
CDK4/6 cyclin-D complex. This leads to dephosphorylation of protein Rb, which in turn 
cannot release transcription factor E2F that binds to DNA to stimulate the synthesis of 
proteins necessary for cell division. No transcription of the genes necessary for the cell 
cycle to progress from G1 to S phase, therefore occurs. If CDK4/6-cyclin D complex is not 
under inhibition, it increases phosphorylation of the retinoblastoma protein (pRb), which 
can then release E2F and transcription will occur and the cell cycle continues from G1 to S 
phase. In tumor cells with defects in p16 or Rb function or a CDK4/6 cyclin D complex 
with increased activity, E2F is constitutively active (Jakubczak et al. 2003) (Figure 1.).  
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Figure 1. p16/Rb pathway. a) In normal cells, when p16 is needed, it inhibits CDK4/6 
Cyclin-D complex that dephosphorylates protein Rb which prevents Rb to interact with 
E2F and the cell cycle is arrested to G1. b). In cancer cells, the E2F transcription factor is 
constantly active and defects in p16, CDK4/6 Cyclin-D complex or pRb, don’t affect on 
cell division. 
2.1.2 Oncogenes 
Oncogenes are typically mutated genes that have an important role in cell signaling 
pathways. They encode proteins that control cell proliferation, apoptosis, or both. They can 
be activated by structural alterations resulting from a mutation or a gene fusion (Konopka 
et al. 1985; Tsujimoto et al. 1985). The most important abnormalities detected are 
mutations involving the ras family of oncogenes. The ras oncogene family has three 
members: H-ras, K-ras, and N-ras. These genes encode a protein on the inner surface of 
the cell membrane with GTPase activity and may be involved in signal transduction. K-ras 
mutations are most commonly seen in 30% in adenocarcinomas of the lung (Westra et al. 
1993).  
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3 Cancer gene therapy 
Cancer is a complex disease requiring combinations of several therapeutic modalities to 
treat it effectively. Gene therapy was originally devised to treat disease by replacing a lost 
or defective gene. Now it has broadened to encompass a variety of approaches of 
introducing genetic materials into cells for therapeutic purposes. These strategies can be 
roughly categorized into two main categories: immunologic and molecular (Heo DS 2002).  
One of the frequently used genetic immunotherapy strategy involves the transfer of the 
genes of the immune-stimulant molecules such as cytokines such as interleukin 12 (IL12) 
gene to boost T-cell mediated immune response against cancer (Shi et al. 2002; Barajas et 
al. 2001). Other approaches includes the manipulation of antigen presenting cells such as 
dentritic cells to enable them of more active tumor antigen presentation in the tumor tissue 
(Vollmer et al. 2002; Vulink et al. 2008) and direct genetic vaccination by the antigen-
encoding genes (Hanke et al. 2002; Grim et al. 2000). 
Molecular approaches involves suicide conversion gene therapy, use of anti-oncogenes to 
inhibit oncogene activity, utilization of tumor suppressor genes, anti-angiogenesis gene 
therapy, transfer the drug resistance genes to overcome the dose-limiting toxicity of 
traditional chemotherapy, the use of anti-viral vectors to deliver anticancer reagents to the 
tumor tissue and also adenovirus gene therapy that will be discussed in the chapters 4-6. 
One of the most investigated suicide gene/prodrug systems is the herpes simplex virus 
thymidine kinase (HSV-TK)/ganciclovir (GCV) system where non-tocix prodrug GCV is 
converted to the toxic form. The efficiency of the system has been demonstrated 
successfully in patients with malignant glioma in a clinical trial where the mean survival of 
patients was prolonged by 81% when treated with TK/GCV therapy after surgery 
(Immonen et al. 2004). 
Anti-oncogenes are mostly targeted against bcl-2, c-myc genes and K ras gene family. 
Treatments with anti-oncogenes have resulted in reduction in tumor growth both in vitro 
and in vivo with melanoma and colon cancer (Hu et al. 2001; Duggan et al. 2001; Chana et 
al. 2002; Tokunaga et al. 2000). 
Successful transfection of the functional wt p53 into cancer cells has showed therapeutic 
outcomes in patients. When combined with radiation, no viable tumor was observed in 
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63% of patients after three month of the completion of the therapy (Swisher et al.2003). 
The main targets for anti-angiogenesis cancer therapy includes inhibiting angiogenic 
inducers (namely, vascular endothelial growth factor and angiopoietin) or introducing 
angiogenic inhibitors such as angiostatin, endostatin, Interleukin-12, and p53 (Chen et al. 
2001).  
One of the main problems with tradiotional chemotherapy is the toxicity to normal cells. 
To protect cells and to enable the use of larger drug doses, drug resistance genes such as 
multiple drug resistance gene-1 (Mdr-1), can be transferred nto the hematopoietic 
progenitors (Licht and Peschel 2002; Koc et al. 1999).  
To improve carriers capacity to deliver anticancer reagents, as well as synthetic 
oligonucleotides, antibodies and RNA, in addition to therapeutic genes, nonviral vectors 
have been developed. Mostly used carriers include liposomes and polymers that can be 
packed with the DNA of desired anticancer agent. Molecules are delivered into cells by 
endocytosis (Wheeler et al. 1996; Sudimak et al. 2000; Qian et al. 2002). 
4 Adenoviral cancer gene therapy 
Adenoviruses are probably the most studied viral gene transfer vectors, but other viruses 
are used as well. Numerous cancer gene therapy studies have been conducted with 
retroviruses (Cole et al. 2005; Thanarajasingam et al. 2007), lentiviruses, vaccinia viruses, 
adeno-associated virus (AAV), and herpes simplex virus to mention but a few (Kirn et al. 
2007; Mueller and Flotte 2008; Pellinen et al. 2004; Tyler et al. 2008).  
4.1 Adenoviruses 
Adenoviruses are nonenveloped DNA viruses. They have a characteristic morphology with 
an icosahedral capsid, which consists of three major proteins: hexon (II), penton base (III), 
and a knobbed fiber (IV), along with minor proteins: VI, VIII, IX, IIIa, and IVa2 (Stewart 
et al. 1993). Highly basic protein VII, small peptide mu, and a terminal protein (TP) are 
associated with DNA. Protein V provides a structural link to the capsid via protein VI 
(Figure 2). Thus far, at least 51 serotypes of human adenovirus have been identified and 
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classified in to six distinct subgroups, A-F (De Jong et al. 1999). Adenovirus serotypes 1-7 
cause the most common infections in humans (Arstila 2004). In the context of gene 
therapy, the most studied adenovirus serotype 5 (Ad5) belongs to subgroup C.  
 
Figure 2. Structure of adenovirus 5 virion. [modified from the figure in (Russell 2000) 
]. 
 
The adenovirus infection cycle can be divided into two phases, early and late, occurring 
before and after virus DNA replication. The first phase covers the entry of the virus into 
the host cell (Figure 3), followed by the passage of the virus genome into the nucleus and 
selective transcription and translation of early viral genes. Early genes are needed for the 
transcription and translation of late genes, which lead to the assembly of structural proteins 
and maturation of the infectious virus. Entry of the virus into the host cell is mediated 
through specific receptors on the target cell. The virus binds to a receptor via the knob 
portion of the fiber. The receptor for adenoviruses belonging to subgroup A-F, but 
excluding subgroup B, is known to be CAR, at least in vitro. (Roelvink et al. 1998). This 
traditionally accepted mechanism of cell entry is now known to be more complex at least 
in vivo after systemic delivery and it is not even known in humans. More intense research 
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is required to reveal virus-host interactions in terms of viral components, blood cell and 
serum interactions of adenoviral vectors and mechanisms behind the adenovirus tropism 
(Baker 2007a and b; Nicklin et al. 2005; Waddington et al. 2008). Some adenovirus 
serotypes seem to have additional binding specificities, suggesting that other receptors 
besides CAR may be needed for the entry (Segerman et al. 2000). After the interaction of 
the virus with the receptor, the entry proceeds via clathrin-mediated endocytosis. The key 
step is the interaction of the penton base arginine-glycine-aspartatic acid (RGD) motif with 
host cell αvβ integrins, leading to endosome formation and internalization. After 
internalization, adenovirus DNA is transported to the nucleus, which is followed by early 
gene protein synthesis. The early gene region consists of four genes: E1, E2, E3, and E4. 
E1 gene products can be subdivided further into E1A and E1B. E1A proteins modulate 
cellular metabolism in a way that makes cell more susceptible to virus replication. They 
interfere with, for instance, the cell division processes and the regulation of NF-κB, p53, 
and pRb proteins. E1B functions cooperatively with E1A by inhibiting apoptosis. E2 is 
also subdivided into two separate transcription regions: E2A and E2B. Their gene products 
(including DNA polymerase) are required for DNA replication. E3 gene products are, on 
the other hand, responsible for defending against the host immune system, enhancing cell 
lysis, and releasing of virus progeny. E4 gene products mainly facilitate virus RNA 
metabolism, promote virus DNA replication, and prevent host protein synthesis. 
Transcription of late genes leads to production of the virus structural components and the 
encapsidation and maturation of virus particles in the nucleus (Russell 2000).  
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Figure 3. Schematic illustration of the adenovirus 5 infection pathway. Cell entry is 
initiated by binding of the fiber knob to its primary receptor CAR, which is followed by 
clathrin-mediated endocytosis. Interaction of the penton base RGD motif with host cell 
integrins (αvβ) is needed for the process to proceed. After endosomal lysis, viral DNA is 
transported to the nucleus, where viral genes are expressed. 
 
Adenoviruses might be useful gene transfer vehicles for treatment of various diseases 
(Bainbridge et al. 2008; Hedman et al. 2003; Immonen et al. 2004; Li et al. 2007; 
Shirakawa et al. 2007). However, clinical trials have shown that uncontrolled, high-dose 
gene transfer and expression could have side effects (Raper et al. 2003). Viruses should 
therefore be targeted to the preferred tissue on a transductional or transcriptional level. The 
former implies restriction of viral entry to target cells, whereas the latter involves selective 
gene expression in the cells of interest. 
4.2 Transductional targeting 
Adenoviruses display unparalleled transduction efficacy and natural tropism to a wide 
range of epithelial tissues. Receptor recognition could be one of the most important factors 
involved in cell tropism. Increased CAR expression appears to have a growth inhibitory 
effect on some cancer cell lines, while loss of CAR expression correlates with tumor 
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progression and advanced disease (Okegawa et al. 2001; Bauerschmitz et al. 2002; Miller 
et al. 1998a; Cripe et al. 2001; Dmitriev et al. 1998). In addition, CAR has been suggested 
to play a role in cell adhesion, and its expression may be cell-cycle dependent (Cohen et al. 
2001). As efficient gene transfer is one of the key issues for successful gene therapy, low 
expression level of CAR on tumor cells causes a major challenge (Okegawa et al. 2001; 
Seidman et al. 2001). To circumvent deficiency of CAR, viruses can be retargeted by 
improving their abilities to attach to heterologous receptors. There are two distinct 
approaches to retarget adenoviruses transductionally: adapter molecule-based targeting and 
targeting via genetic manipulation of the adenovirus capsid (Figure 4). 
 
 
Figure 4. Transductional targeting of adenoviruses. Transductional targeting can be 
used to target adenovirus to alternative cellular receptors instead of its primary receptor 
CAR. Targeting can be based on use of adapter molecules or genetically modified fibers 
that allow the virus to bind alternative receptors. 
4.2.1 Adapter molecule-based targeting 
The idea behind adapter molecule-based targeting is to use adapter molecules that 
crosslink the adenovirus vector to alternative cell surface receptors, bypassing the native 
CAR-based tropism (Figure 4). The majority of currently used adapter molecules are 
bispecific , which both ablates the native CAR binding and formats a novel tropism to 
cellular receptors, highly expressed on cancer cells. Various adapter molecules from 
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bispecific antibodies, chemical conjugates between antibody fragment (Fab) and cell 
selective ligand (ex. folate), Fab antibody and peptide ligand conjugates to recombinant 
fusion proteins that incorporate Fabs and peptide ligands have been used successfully. 
The first in vitro study of adenovirus targeting via adapter molecule was done by Douglas 
et al (Douglas et al. 1996). They targeted to the folate receptor, overexpressed on many 
malignant cells with anti-knob neutralizing Fab-folate conjugate. A similar targeting 
system was used with FGF receptor-positive Kaposi's sarcoma (KS) cells in vitro, where 
basic fibroblast growth factor (FGF2) was fused to anti-knob Fab (Goldman et al. 1997). 
Other Fab-ligand conjugates have been targeted to epithelial cellular adhesion molecule 
(Ep-CAM) (Haisma et al. 1999) , tumor-associated glycoprotein (Tag-72) (Kelly et al. 
2000), epidermal growth factor (EGF) receptor (Miller et al. 1998b), and CD 40 cell 
marker (Tillman et al. 1999), with promising results. 
An interesting alternative method to the chemical conjugates was developed utilizing a 
truncated soluble form of CAR (sCAR) fused to EGF (Dmitriev et al. 2000). Approaches 
resulted in increased reporter gene expression in many cancer cell lines overexpressing 
either EGF receptor or CD40 in vitro. When targeted to the EGF receptor, up to a 9-fold 
increase in gene transfer was seen compared with nontargeted adenovirus. 
The above approaches have also been tested in vivo. A bispecific antibody was used to 
target adenovirus to the angiotensin-converting enzyme (ACE) expressed in the pulmonary 
capillary endothelium. Systemic delivery of adenovirus resulted in a 20-fold increase in the 
lungs compared with the untargeted control. Moreover, adenovirus gene transfer to liver 
decreased 83% (Reynolds et al. 2000). Another unique lung-targeting approach was 
developed by Everts et al, where sCAR was fused with with a single-chain anti-CEA 
antibody (MFE-23). sCAR-MFE targeted adenovirus decreased liver gene expression by > 
90 % and increased transduction to the CEA-positive epithelial tumor cells after systemic 
delivery (Everts et al. 2005; Li et al. 2007).  
4.2.2 Genetic targeting  
The advantage of the adapter-based targeting approach is the wide range of ligands that 
can be incorporated into fusion molecules, but there are also several drawbacks. The 
structure itself is complex, which results in creation of a heterogeneous population of 
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virions, and the stability of the complexes in the human circulation is not very well 
characterized. This might be disadvantageous in human trials. Therefore, one-component 
systems where adenoviruses capsid proteins are genetically manipulated have been created. 
Overall, there are three basic ways to modify adenovirus fiber to redirect its tropism: 1) so-
called fiber pseudotyping, 2) ligand incorporation into the fiber knob, and 3) ‘de-knobbing’ 
of the fiber coupled with ligand addition. 
Understanding of adenovirus infection biology indicates that genetic modifications are 
usually located in the fiber, the primary capsid determinant of adenoviral tropism. Many 
clinically relevant cancer cell types are refractory to adenovirus infection due to variable or 
aberrant expression of the primary receptor CAR (Bauerschmitz et al. 2002; Cripe et al. 
2001; Hemminki et al. 2002; Miller et al. 1998a; Okegawa et al. 2000; Seidman et al. 
2001). Genetic replacement of fiber knob was first accomplished by Krasnykh et al 
(Krasnykh et al. 1996). Adenovirus serotype 5 knob was replaced by the knob from 
serotype 3, which uses a different receptor than Ad5 in cell entry. Ad3 belongs to subgroup 
B and primary receptors for adenoviruses belonging to the group have recently been 
suggested, including CD46, a complement regulatory protein expressed on the surface of 
nucleated human cells (Liszewski et al. 1991), and CD80 and CD86, costimulatory 
molecules present on mature dendritic cells and B lymphocytes and involved in stimulating 
T-lymphocyte activation (Short et al. 2004). The receptor for adenovirus 3 is still 
unknown, although there are suggestions that it could be on one of the above receptors or 
some coreceptor or combination of receptors (Sirena et al. 2004; Tuve et al. 2006a; Sirena 
et al. 2004). Ad5/3 chimera has displayed enhanced CAR independent transduction on 
variety of neoplastic cells (Krasnykh et al. 1996; Davidoff et al. 1999; Kanerva et al. 
2002b). Promising results with Ad5/3 chimeras have encouraged many researchers to 
evaluate other serotype chimeras. Ad5/35, Ad5/11, and Ad5/7 have shown enhanced 
transduction refractory to the CAR in many types of cells with clinical importance and 
reduced localization to the liver (Shayakhmetov et al. 2000; Stecher et al. 2001; Gall et al. 
1996; Mizuguchi & Hayakawa 2002; Schoggins et al. 2005).  
The fiber knob region is the major attachment site for the primary receptor at least in vitro. 
Consequently, modification of the knob region has become a major research focus for 
targeting gene delivery. Studies have exploited two locations within the knob, C-terminus 
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and HI loop, which can be manipulated without losing function of the fiber. Since the C-
terminus is solvent-exposed, Wickham et al. added a polylysin tail to mediate adenovirus 
binding through heparan sulfate proteoglycans (HSPGs), yielding promising results 
(Wickham et al. 1997; Kangasniemi et al. 2006; Ranki et al. 2007a). αvβ integrin-binding 
arginine-lysine-aspartic acid (RGD) motifs have also successfully been incorporated into 
the C-terminus (Wickham et al. 1997). Another promising knob location, the HI-loop, 
which is exposed outside and can tolerate rather large (up to 100 amino acids) peptide 
insertions, is located between β-strands H and I in the knob monomer. FLAG peptide was 
introduced to the site first by Krasnykh et al, and other retargeting motifs in the HI loop 
have been evaluated. RGD-4C peptide in the HI loop is widely used with enhanced 
infectivity to wide range of tumor cells in vitro and in vivo (Cripe et al. 2001; Dmitriev et 
al. 1998; Hemminki et al. 2001; Kanerva et al. 2002b; Kangasniemi et al. 2006; Ranki et 
al. 2007a). Other peptide that has provided cancer selective targeting when inserted into 
the HI loop includes asparagine-glycine-arginine (NGR) (Mizuguchi et al. 2001).  
Wu et al, combined a polylysin tail in the C-terminus and a RGD-4C motif in the HI loop, 
and enhanced gene transfer was achieved with several CAR-deficient cell lines, as well as 
with human pancreatic islet cells (Wu et al. 2002). Some studies have also used both 
genetic fiber modification and an adapter-based approach where incorporating proteins 
with immunoglobulin binding domains into the C-terminus or the HI loop resulted in 
enhanced gene transduction in cells containing the Fc region of Ig (Henning et al. 2005; 
Korokhov et al. 2003; Volpers et al. 2003).  
Since the ligand incorporation methods described above do not necessarily ablate CAR 
binding, a native fiber has been replaced by a knobless fiber and simultaneous adding of 
targeting ligand to the fiber has resulted in a more targeted adenovirus (Falgout and Ketner 
1988; Von Seggern et al. 1999). However, the major barrier to this approach is that the 
knob region contains a stabilization element for the fiber element. To circumvent the 
problem, external trimerization elements, such as the bacteriophage T4 fibritin or the neck 
region of human lung surfactant protein D (NRP), have been used (Hedley et al. 2006; 
Krasnykh et al. 2001; Magnusson et al. 2001). Li et al. described a novel trimerization 
element within the adenovirus fiber protein containing an N-terminus tail and shaft repeats 
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that was able to form stable virions and serve as a platform for the generation of tissue-
specific adenovirus vectors (Li et al. 2006).  
The need for targeting adenoviruses has lead to searches for other capsid proteins that 
could be manipulated such as hexon, penton, and pIX. Due to the location of the hexon 
protein, it is an attractive site for incorporating targeting ligands. Hexon hypervariable 
regions have a loop that protrudes outside the capsid and Vigne et al. exploited the 
possibility to attach an RGD motif to this loop. Notably, the stability of the virion was 
unaffected and enhanced gene delivery to non CAR cells was achieved (Vigne et al. 1999). 
The RGD motif in the penton base was replaced with a peptide that targeted adenoviruses 
to the metastatic melanomas and glioblastomas (Wickham et al. 1995). Recently, pIX was 
found to be a versatile capsid location suitable for both targeting and imaging motifs 
(Dmitriev et al. 2002; Le et al. 2004).  
4.3 Transcriptionally targeted adenoviruses 
To achieve more tumor cell-selective adenoviruses, gene expression can be regulated 
transcriptionally. Regulation is usually mediated by tumor-specific promoters. 
Transcriptional targeting of adenovirus transgene expression or replication restricts the 
transcription unit expression to the cells where the promoter being used is active. A 
number of tumor, or tissue-specific promoters have been applied in cancer gene therapy 
(Glasgow et al. 2004; Saukkonen & Hemminki 2004). Table 1 summarizes some of these. 
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Table 1. Selected tumor-specific promoters used in adenoviral gene therapy. 
Promoter Transgene(s) Disease application Reference 
CEA LacZ 
HSVtk 
Gastric cancer 
Lung cancer 
(Brand et al. 1998; 
Osaki et al. 1994).  
SLPI HSVtk Ovarian cancer (Barker et al. 
2003a).  
Cox-2 HSVtk 
Luciferase 
HSVtk 
HSVtk 
 
Luciferase 
Gastric cancer 
Pancreatic cancer 
 
Ovarian cancer 
 
Lung cancer 
 
(Yamamoto et al. 
2001).  
(Wesseling et al. 
2001).  
(Casado et al. 2001). 
(Sarkioja et al. 
2008).  
 
Midkine (MK) Luciferase 
HSVtk 
Pancreatic cancer 
 
(Wesseling et al. 
2001).  
hTERT 
 
 
E1A_IRES_E1B 
GFP/TRAIL 
 
Lung cancer 
Breast cancer 
 
(Hashimoto et al. 
2008).  
(Lin et al. 2002).  
E2F E1A Lung cancer 
Ovarian cancer 
(Tsukuda et al. 
2002).  
CXCR4 E1A 
E1A 
E1A 
Lung cancer 
Breast cancer 
Renal cancer 
(Zhu et al. 2007b).  
(Rocconi et al. 
2007).  
(Haviv et al. 2004).  
SCCA2 Luciferase Lung cancer (Oshikiri et al. 
2006).  
TTS  Lung cancer (Fukazawa et al. 
2004).  
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Abbreviations used: CEA, carcinoembronic antigen; SLP1, secretory leukoprotease inhibitor; Cox-
2, cyclooxygenase 2; hTERT, human telomerase reverse transcriptase; CXCR4, chemokine 
receptor; SCCA2, squamous cell carcinoma antigen; TTS, dual promoter with hTERT and human 
surfactant protein A1 promoters. 
Carcinoembryonic antigen (CEA) promoter was one of the first tissue-specific promoters 
explored. CEA is expressed in many types of cancers. Herpes simplex virus thymidine 
kinase (HSVtk) expression driven by the CEA promoter left CEA-negative cell lines 
resistant to ganciclovir (GCV) prodrug therapy, while CEA-positive A549 cells were 
1000-fold more sensitive (Osaki et al. 1994). Further, Hashimoto et al. used human 
telomerase reverse transcriptase promoter (hTERT)-driven adenovirus E1A and E1B genes 
connected to the internal ribosome entry site (IRES) to target lung cancer cells in vitro and 
in vivo, which led to a 50% reduction in cell viability in normal cells versus lung cancer 
cells (Hashimoto et al. 2008). In addition, E2F, CXCR4, SCCA2, and TTS have been used 
to target adenoviruses to lung cancer tissue, with promising results. E2F transcription 
factors are critical regulators of cell growth and are often overexpressed in cancer cells 
because of frequent aberrations in the pRb/E2F/p16(INK4a) pathway. As a result, a 
majority of tumor cells exist in a high proliferative state with E2F constantly active, 
making it a good candidate promoter for targeting adenovirus (Tsukuda et al. 2002). 
Chemokine receptor CXCR4 is highly expressed in lung cancer and CXCR4 promoter-
driven RGD-modified adenovirus showed a 10-fold increase in replication in lung cancer 
tissue slices, in contrast to a 10-fold decrease in the human liver slices (Spano et al. 2004; 
Zhu et al. 2007b).  
In addition to tissue-specific promoters, adenoviral transgene expression or replication can 
also be controlled at a posttranscriptional level. Eukaryotic mRNAs contain 3'-untranslated 
regions (UTRs), the AU- rich elements of which are involved in posttranscriptional control 
of gene expression. These elements are frequently present in 3-UTRs of many proto-
oncogene and cytokine mRNAs (Dixon et al. 2000; Kruys et al. 1989). The usual 
physiological function of the elements is to rapidly downregulate mRNA transcripts when 
the threat (e.g. infection) has passed. Ahmed et al. used CMV promoter-driven adenovirus, 
where the E1A was under the regulation of the 3’UTR element from the cyclooxygenase 2 
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(Cox-2) gene, allowing RAS/P-(MAPK)-specific stabilization on the mRNA (Ahmed et al. 
2003).  
Tumor-specific promoters and other regulatory elements have the potential to increase 
specificity and decrease toxicity of adenoviral gene therapy. However, adenoviruses 
targeted only with promoters or regulators are dependent on CAR for entry. Combining 
transductional and transcriptional targeting is an effective way to achieve a synergistic 
effect on gene transfer (Barker et al. 2003b; Reynolds et al. 2001).  
5 Oncolytic adenoviruses  
Although nonreplicating first-generation adenoviruses have provided high in vitro and in 
vivo transduction rates and good safety data, clinical trials have suggested that the single-
agent antitumor effect may not be sufficient for all treatment approaches. Advanced human 
solid tumor masses are larger and more complex than xenograft tumors, which restrict 
sufficient access of virions to tumor cells. Necrotic, hyperbaric, hypoxic, and stromal areas 
can for instance, be problematic. To overcome this problem, oncolytic adenoviruses have 
been developed. Their antitumor effect is based on oncolysis caused by replication per se, 
whereas normal tissues are spared due to low replication (Figure 5). Hypothetically, the 
replication would continue until all cancer cells are lysed, and released viruses would even 
disseminate into the bloodstream and infect distant metastasis. 
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Figure 5. Oncolytic adenoviruses. A) Infection of tumor cells results in viral replication, 
cell lysis, and release of new viruses. B) Normal cells are spared due to lack of replication. 
 
Adenovirus early 1 (E1) gene is responsible for replication and most development of 
oncolytic adenoviruses have focused on the genetic engineering of E1 genes. There are two 
approaches that have been used to restrict viral replication to target cells and to spare 
normal tissue. The first published oncolytic adenovirus, d11520, later called ONYX-015 
has two mutations in the E1B gene coding the E1B-55kD protein and is very similar to the 
H101, the first licensed oncolytic agent (Bischoff et al. 1996; Xia et al. 2004b). 
Adenovirus E1B-55kD protein binds to tumor suppressor p53 to inactivate it for induction 
of S-phase-like state, which is required for viral replication. Further, it is responsible for 
forming a different complex with E4orf6 that shuts off host mRNA nuclear export and host 
protein synthesis. It also facilitates the nuclear localization of transcription factor YB1 to 
activate the E2 late promoter (Holm et al. 2002). Tumor cells often have an inactivated 
p53-p14ARF pathway, and thus, viruses should only replicate in these cells. However 
some tumor cells seem to fail to support E1B-55kD deleted adenoviral replication. 
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Recently O’Shea et al suggested that it may be due to failure in late mRNA export that 
prevents host protein shutoff (O'Shea et al. 2005).  
Another type of Ad contains a 24 bp deletion in constant region 2 (CR2) of the E1A gene. 
This domain is responsible for binding the Rb tumor suppressor/cell cycle regulator 
protein, thereby allowing adenovirus to induce an S-phase-like state. As a result, viruses 
with the Δ24-E1A deletion have a reduced ability to overcome the G1-S checkpoint and 
replicate efficiently only in cells where this interaction is not necessary, e.g. in tumor cells 
defective in the Rb-p16 pathway. (Heise et al. 2000b; Fueyo et al. 2000; Suzuki et al. 
2001).  
A third type of deletion used to confer cancer selectivity to adenovirus is the deletion of 
virus-associated (VA) RNA genes. These small type I and II RNAs inactivate the protein 
kinase R (PKR). PKR plays a major role in the interferon (IFN) antiviral cell defense, and 
by binding to PKR, VA-RNAs counteract this IFN response to adenovirus, and conversely, 
adenoviruses defective in VA-RNAs are blocked by IFN via protein translation inhibition. 
However, many cancer cells present a truncated IFN pathway, and adenoviruses with VA 
RNAs deleted retain replication in these cells, but not so in normal cells (Cascallo et al. 
2003; Cascallo et al. 2006).  
In addition, viral replication can be restricted to target cells by using tumor-specific 
promoters (TSPs). TSPs are usually added to control EIA, but alternatively, other genes 
such as E4 can also be regulated. Various promoters have been used and some selected 
ones are presented in Table 1. 
5.1 Oncolytic adenoviruses combined with targeting moieties 
To improve adenovirus-based replication in the context of clinically applicable cancer gene 
therapy, it is essential to increase targeting to tumor cells and decrease targeting to the liver 
due to possible toxicity. Adenovirus 5-based oncolytic viruses may fall victims to variable 
CAR expression, and a number of strategies exists to improve Ad5 based viral tropism. 
Previously described transductional targeting methods have been combined with oncolytic 
viruses with good results. Serotype chimeric Ad5/3-Δ24 has shown increased therapeutic 
efficacy at least in ovarian, kidney, breast, and gastric cancers (Kanerva et al. 2003; Guse 
et al. 2007b; Kangasniemi et al. 2006; Ranki et al. 2007a). Ad5-Δ24RGD, which has RGD 
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modification in the HI loop also has shown efficient cell killing in numerous cancer cells, 
including ovarian cancer, glioma and osteosarcoma (Lamfers et al. 2002; Suzuki et al. 
2001; Witlox et al. 2004). Further, Ranki et al. added seven polylysins to the C-terminus of 
the Ad5Δ24 creating Ad5.pK7-Δ24, which displayed enhanced oncolysis of breast cancer 
cells in vitro and in vivo (Ranki et al. 2007).  
Recent studies have utilized double, or even triple-targeted adenoviruses to achieve more 
specificity. Combining a transductional targeting moiety with a tumor-specific promoter 
has resulted in a pancreatic and ovarian cancer specific adenovirus featuring Ad3 knob and 
Cox-2 promoter driving E1A with a 24 bp deletion in the CR2 (Bauerschmitz et al. 2006; 
Ramirez et al. 2008). Guse et al. used many double- and triple-targeted adenoviruses with 
Ad3 knob, RGD, and pK7 motifs combined with Cox-2 promoter driving CR1 and/or CR2 
deletions with promising results in ovarian and renal cancer xenografts (Guse et al. 2007a).  
5.2 Armed oncolytic adenoviruses 
Despite successful targeting and specific replication of oncolytic adenoviruses in the tumor 
tissue, clinical trials with early generation adenoviruses have shown that complete 
eradication of solid tumor masses rarely occurs. This might be due to intratumoral 
complexities such as stromal matrix and other extracellular barriers within the tumor tissue 
(Cheng et al. 2007). A useful approach for improving the potency of replicating agents is 
to arm viruses with therapeutic transgenes, e.g. genes encoding prodrug-converting 
enzymes (Hermiston and Kuhn 2002). Common approaches include HSV-TK and 
Escherichia coli cytosine deaminase (CD), which convert nontoxic prodrugs [ganciclovir 
(GCV) and 5-fluorocytosine, respectively] into cytotoxic metabolites. The activated drugs 
can spread into surrounding cells creating a so called bystander effect.  
Reports combining a TK/GCV system with replicating adenoviruses have been rather 
controversial. Some studies have demonstrated that GCV enhances oncolytic potency of 
adenoviruses expressing HSV-tk (Nanda et al. 2001; Raki et al. 2007; Wildner et al. 
1999), in contrast to others where oncolytic potential was not improved possibly due to the 
inhibition of viral replication by GCV(Hakkarainen et al. 2006; Lambright et al. 2001; 
Morris & Wildner 2000; Wildner & Morris 2000). Double suicide therapy with both HSV-
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tk and CD genes has proven to be rather efficient, especially when combined with 
radiotherapy (Freytag et al. 1998; Rogulski et al. 2000; Wu et al. 2005).  
 
5.3 Oncolytic adenoviruses in combination with conventional therapies 
Combining adenoviral gene therapy with traditional therapies is a powerful tool to achieve 
enhanced or even synergistic cell killing and antitumor efficacy. The mechanism of the 
additive or synergistic effect of combined therapy is not yet thoroughly known, although a 
few hypotheses have been tendered. Firstly, expression of adenoviral E1A protein may 
sensitize cells to chemotherapy or radiotherapy-mediated cell killing (Duque et al. 1998; 
Sanchez-Prieto et al. 1996). Secondly, chemotherapeutic agents may enhance the level of 
virus replication. Finally, chemotherapeutic agents may affect the receptor status of the 
target cells or each agent may work independently within the tumor tissue.  
There are a number of studies where oncolytic adenoviruses have been combined with 
chemo- or radiotherapy, and some of them have even proceeded to clinical testing. ONYX-
015 was the first virus to undergo clinical trials combined with chemotherapy. ONYX-015 
was combined with 5-fluorouracil (5-FU) and cisplatin to treat squamous cell carcinoma of 
the head and neck carcinoma (Xia et al. 2004a; Khuri et al. 2000a). ONYX-015 was also 
combined with gemcitabine (pancreatic cancer) (Hecht et al. 2003), mitomycin 
C+doxorubicin + cisplatin (MAP) (advanced sarcoma) (Galanis et al. 2005a), and 
carboplatin + taxol (lung metastasis) (Nemunaitis et al. 2001), among other but a few 
studies. Chemo- and radiotherapies were combined with HSV-tk and CD-expressing 
adenovirus to treat prostate cancer with good safety data (Freytag et al. 2003b); these 
treatments may provide a potential long-term benefit for the patients (Freytag et al. 2007).  
5.4 Cells as carriers of oncolytic adenoviruses  
Although infectivity and specificity of adenoviruses can be enhanced, obstacles remain 
that may hinder the bioavailability of viruses, especially after intravenous administration. 
Despite retargeting, the majority of systemically administered adenoviruses are taken up 
by Kupffer cells in the liver, decreasing the amount of available virus (Alemany et al. 
2000). In addition, adaptive and innate immune responses may eliminate therapeutic 
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viruses (Bessis et al. 2004). Further, tumors are known to be very heterogeneous in 
structure, containing hypoxic, necrotic, and stromal areas, which may hinder spreading of 
the adenovirus within the tumor. A potential solution to solve these problems is the use of 
cells as viral carriers (Sanz et al. 2005; Raykov and Rommelaere 2008; Fritz and Jorgensen 
2008). This might have advantages over systemic viral administration, as attenuated 
neutralization and improved viral targeting could result in smaller viral doses administered 
to patients, which may in turn reduce the systemic side effects. However, the use of cells as 
agents for systemic virus delivery depends on 1) their ability to be transduced with 
adenovirus, 2) their ability to allow the replication and release of oncolytic adenoviruses 
and 3) their ability to home specifically to tumor. There a several cell types that have been 
used as carriers of viruses suchs as antigen-specific T-cells (Cole et al. 2005; Yotnda et al. 
2004), macrophages (Griffiths et al. 2000), endothelial progenitor cells (Jevremovic et al. 
2004), non antigen specific T-cells (Ong et al. 2007) and mesenchymal stem cells 
(MSCs)(Dvorak 1986; Studeny et al. 2004a).  
MSCs are precursor cells that originate either from e.g. bone marrow or fat tissue, and they 
can differentiate into adipocytes, chondrocytes, osteoblasts, myoblasts, and tenocytes 
(Prockop 1997). One function of the MSCs is to repair injured tissue, and it is also 
hypothesized that the tumor environment resembles injured tissue, and therefore, 
circulating MSCs would home to tumors. (Dvorak 1986; Studeny et al. 2002; Studeny et 
al. 2004a). In some studies adenoviruses have been targeted to tumor tissue using MSCs as 
carriers. Nakamura et al. targeted adenoviral vector coding human interleukin-2 within 
MSCs with an augmented antitumor effect and prolonged survival of glioma-bearing rats 
(Nakamura et al. 2004). Stoff-Khalili et al used hMSCs to target oncolytic adenovirus in to 
lung metastases of breast cancer which reduced the growth of lung metastases in vivo 
(Stoff-Khalili et al. 2007a).  
6 Clinical trials with oncolytic adenoviruses 
Cancer is a complex disease that often eludes successful treatment due to its propensity to 
evolve or adapt in the face of current therapeutic regimes. Viral oncolytic therapy has been 
37 
 
under investigation as a novel anticancer strategy and the first cancer trial with wild type 
adenovirus was done as early as 1950s. Since the late 1990s oncolytic adenoviruses have 
been utilized to treat phase I-III cancer patients. The first oncolytic adenovirus used in a 
clinical trial was ONYX-015, which has a 55 kb deletion in the E1b gene, and thus, has 
tumor selectivity to cancer cells with mutant p53. The virus established a clinical proof-of-
concept for oncolytic virotherapy in a first phase I trial in which the virus was directly 
injected into head and neck tumors with 14% regression rates (Ganly et al. 2000; 
Nemunaitis et al. 2000). When ONYX-015 was combined with cisplatin and 5-FU in the 
phase II trial, approximately 65% of patients showed tumor regression (Khuri et al. 2000b; 
Nemunaitis et al. 2000). A phase III trial was done in China with a closely related virus 
H101 and investigators reported 79% response rate in combination-treated patients versus 
40% in controls without virus treatment (p<0.001) (Xia et al. 2004b) and later the virus got 
a official selling permit in China.  
Another oncolytic adenovirus used in clinical trials is CV706. CV706 is a prostate-specific 
antigen (PSA)-selective, replication-competent adenovirus that showed in the phase I study 
good safety data and intraprostatic replication (DeWeese et al. 2001). In addition, another 
prostate specific, intravenously administered virus cg 7870 has been used in phase I study 
to treat hormone refractory metastatic prostate cancer with promising safety data (Small et 
al. 2006). Overall, trials with onvolytic adenoviruses have reported good safety data, but 
only marginal efficacy. Selected oncolytic adenovirus trials are summarized in Table 2. 
For a more detailed listing of gene therapy trials, see 
http://www.abedia.com/wiley/index.html. 
Table 2. Clinical trials with oncolytic adenoviruses. 
Virus/treatment Genetic 
modification  
Phase Route Max.dose Disease Beneficial/ 
total 
Reference 
ONYX-015 E1b-55 kD 
deletion 
I i.t. 1x1011pfu SCCHN 2/22 (Ganly et 
al. 2000).  
 
ONYX-015 E1b-55 kD 
deletion 
I i.t. 1x1011pfu Pancreatic 
cancer 
0/23 (Mulvihill 
et al. 2001). 
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ONYX-015 E1b-55 kD 
deletion 
I i.v. 2x1013vp Cancer 
metastatic 
to lung 
0/10 (Nemunaitis 
et al. 2001). 
 
ONYX-015 E1b-55 kD 
deletion 
I i.p. 1x1011pfu/d 
x 5d 
Ovarian 
cancer 
0/16 (Vasey et 
al. 2002).  
 
ONYX-015+ 
5-FU+ 
leucovorin 
E1b-55 kD 
deletion 
I i.ha. 2x1012vp Colorectal 
cancer 
metastatic 
to liver 
1/11 (Reid et al. 
2001).  
 
ONYX-015 E1b-55 kD 
deletion 
I i.t. 1x1010 pfu Glioma 3/24 (Chiocca et 
al. 2004).  
 
ONYX-015+ 
etanercept 
E1b-55 kD 
deletion 
I i.v. 1x1012pfu Advanced 
ca. 
0/9 (Nemunaitis 
et al. 2007). 
 
        
CV 706 
 
PSA 
promoter-
enhancer 
contr. E1A 
I i.t. 1x1013vp Prostate 
cancer 
5/20 (DeWeese 
et al. 2001). 
 
Ad5- 
CD/TKrep  + 
GCV/ 5-FU +  
radiation 
E1b-55 kD 
deletion + 
TK/CD  
 
I i.t. 1x1012vp Prostate 
cancer 
15/15 (Freytag et 
al. 2003a).  
 
ONYX-015 + 
5-FU 
E1b-55 kD 
deletion 
I-II i.t. 
i.ha. 
i.v. 
3x1011pfu HCC and 
colorectal 
cancer 
metastatic 
to liver 
3/16 (Habib et 
al. 2001).  
 
ONYX-015 E1b-55 kD 
deletion 
II i.t. 2x1011 vp 
X 10d 
SCCHN 5/40 (Nemunaitis 
et al. 2001). 
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Abbreviations used: i.t., intratumoral; i.v., intravenous; i.p., intraperitoneal; i.ha, intrahepatic artery, 
5-FU, 5-fluorouracil; MAP, mitomycin C+doxorubicin + cisplatin; SCCHN, squamous cell 
carcinoma of the head and neck; vp, viral particles; pfu, plaque-forming units; HSV-tk, herpes 
simplex virus thymidine kinase; CD, cytosine deaminase 
7 Adenoviruses and immune response 
Effective readministration of adenovirus might be important factor in achieving full 
potential of adenoviral gene therapy for treating many diseases. More than 50 different 
 
ONYX-015 + 
cisplatin and   
5-FU 
E1b-55 kD 
deletion 
II i.t. 1x1010vp/d 
X 5d 
SCCHN 19/37 (Khuri et al. 
2000a).  
 
ONYX-015 + 
Gemcitabine 
E1b-55 kD 
deletion 
I-II i.t. 2x1011vp/wk 
8 cycles 
Pancreatic 
cancer 
2/21 (Hecht et 
al. 2003).  
 
ONYX-015 E1b-55 kD 
deletion 
II i.v. 2x1012vp/ 2 
weeks 
Metastatic 
colorectal 
cancer 
0/18 (Hamid et 
al. 2003).  
 
CG7870 Rat probasin 
controlling 
E1A 
I-II i.t. 1x1013vp Prostate 
cancer 
10/20 DeWeese 
2003 
H101 +  
cisplatin/ 
adriamycin +  
5-FU 
E1b-55 kD 
deletion 
III i.t. 1.5x1012vp/d 
X 5d 
SCCHN 71/160 (Xia et al. 
2004b).  
 
ONYX-015 + 
MAP 
chemotherapy 
E1b-55 kD 
deletion 
1-II i.t. 5x1010 pfu Sarcoma 1/6 (Galanis et 
al. 2005b).  
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serotypes of adenoviruses are known to infect humans. Due to the ubiquitous nature of 
adenoviruses, a majority of the human population has been exposed to them (also to Ad5), 
leading to the development of adenovirus-specific neutralizing antibodies (NAbs). A high 
neutralizing antibody titer might not be a limiting factor in local treatment (Cichon et al. 
2001; Hodges et al. 2005), but it can decrease the bioavailability of systemically 
administered adenoviruses. NAbs can be induced against all adenoviral capsid proteins, 
such as hexon, penton and fiber and there may even be synergy between them (Gahery-
Segard et al. 1998; Rahman et al. 2001). Strategies that are being examined to circumvent 
immune response to adenovirus vectors include immunosuppression, immunomodulation, 
serotype switching, use of targeted adenovirus vectors, microencapsulation of adenovirus 
vectors, use of helper-dependent (HD) adenovirus vectors, and development of nonhuman 
adenovirus vectors. 
7.1 Manipulation of adenoviruses to circumvent immune response 
Following intravenous inoculation, adenoviruses are generally taken up by Kupffer cells in 
the liver, and by macrophages in the spleen leading to rapid induction of an innate immune 
response. The innate immune response is activated following recognition of molecular 
patterns on the adenovirus capsid by receptors on macrophages and dendritic cells (DCs), 
resulting in activation of multiple signaling pathways, such as mitogen-activated protein 
kinase (MAPK) and nuclear factor (NF)-κB pathways, that augment expression of several 
proinflammatory cytokines and chemokines (Bruder and Kovesdi 1997; Lieber et al. 1997; 
Muruve et al. 1999). The use of such immunosuppressive agents as cyclosporine and 
cyclophosphamide to block antibodies raised against adenovirus enhances the duration of 
transgene expression (Smith et al. 1996). Since macrophages in the liver activate the 
immune response, there are approaches where depletion of macrophages and dendritic 
cells has resulted in increased transgene expression (Ranki et al. 2007b; Schiedner et al. 
2003). Further, alteration of the immunodominant epitopes of adenovirus capsid can also 
help to evade immune response. Covalent attachment of polymers, such as polyethylene 
glycol (PEG), to the adenovirus capsid has been shown to inhibit antibody-mediated virus 
neutralization but there is evidence that it also decreases tumor transduction of the virus 
(Croyle et al. 2002; Croyle et al. 2005).  
41 
 
Adenoviral serotypes are classically determined based on neutralization assay and it is 
therefore logical that different serotype can overcome NAb. In some studies, serotype 
switching in vector construction has helped to overcome immune response (Kass-Eisler et 
al. 1996; Mastrangeli et al. 1996). Especially the use of subgroup B adenoviruses, such as 
Ad3, Ad11 and Ad35 has been promising since these are not dependent on CAR-mediated 
internalization and can evade pre-existing Ad5 immunity (Barouch et al. 2004; Stone et al. 
2005; Vogels et al. 2003; Kanerva et al. 2002b). The adenoviral fiber knob has been 
shown to induce DC activation and maturation (Molinier-Frenkel et al. 2003), and 
therefore, fiber knob modifications to incorporate cellular ligands with novel cell-binding 
capacity might confer targeting and be one way to decrease vector immunogenicity (Nanda 
et al. 2005) Adenoviral microencapsulation with, for instance, polyethylene glycol-cationic 
lipid and poly (lactic-glycolic) acid (PLGA) copolymer has been demonstrated to guard 
adenovirus vectors from neutralizing antibodies and to be capable of effective transduction 
and gene expression on target cells (Beer et al. 1998; Chillon et al. 1998; Steel et al. 2004).  
Lastly, utilization of helper dependent (HD) adenoviruses has resulted in controversial 
results in evading immune response. HD adenoviral vectors lack all coding sequences of 
the adenovirus genome, except the packaging sequence and inverted terminal repeats, have 
been shown to elicit minimal cell-mediated immune response (Morsy et al. 1998) but led 
to acute toxicity accompanied by activation of the innate immune response after systemic 
administration in baboons (Brunetti-Pierri et al. 2004).  
To extend the range of Ad vectors that can be used to evade human adenovirus neutralizing 
immune response, a number of nonhuman adenoviruses, such as bovine Ad type 3 (BAd3), 
canine Ad type 2, porcine Ad type 3, ovine Ad ,and chimpanzee Ad have been exploited 
for gene transfer, without hindrance from cross-neutralizing effects (Bangari & Mittal 
2004; Farina et al. 2001; Hemminki et al. 2003; Hofmann et al. 1999; Mittal et al. 1995).  
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Aims of the study 
1. To determine the best receptor binding motif for NSCLC cell lines and fresh 
NSCLC primary tissue samples in vitro and in vivo and to evaluate gene transfer 
and antitumor efficacy of oncolytic adenoviruses through non-CAR receptors. In 
addition, the biodistribution, and the oncolytic potency of adenoviruses were 
evaluated in vivo with noninvasive imaging. (I). 
2. To examine the capacity of capsid-modified adenoviruses to infect and replicate in 
MSCs. Further, biodistribution, tumor-homing ability, and tumor-killing efficacy 
of systemically delivered, virus-loaded MSCs in orthotopic lung and breast cancer 
tumor models were evaluated (II). 
3. To investigate induction of the Cox-2 promoter both in normal and tumor cells 
after adenovirus infection and to explore the utility of AU-rich elements for 
regaining promoter selectivity (III). 
4. To evaluate whether changing the adenovirus fiber knob could allow the virus to 
overcome pre-existing adenoviral NAbs in the context of low or high NAb titer, in 
mice with advanced orthotopic NCSLC, and in human clinical samples of both 
cancerous and nonmalignant lung tissue (IV). 
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Materials and methods 
Detailed description of the methodologies used can be found in the original publications. 
1 Cell lines, human mesenchymal stem cells (MSCs), and 
primary NSCLC (I-IV) 
Table 3. Human cell lines used in studies I-IV. 
Cell line Description Source Study 
293 
ATCC CRL-1573 
 
Transformed embryonic 
kidney cells 
ATCC (Manassas, 
VA) 
I,III 
NCI-H460 
HTB-177 
Lung large-cell 
carcinoma 
ATCC  I 
NCI-H661 
HTB-183 
Lung large-cell 
carcinoma 
ATCC  I 
LNM35/EGFP Lung large-cell 
carcinoma expressing 
enhanced green 
fluorescent protein 
Takashi Takahashi 
(Honda Research 
Institute, Japan) 
I,II, III, IV 
SW900 
HTB-59 
Lung squamous cell 
carcinoma 
ATCC  I 
Ma44-3 Lung squamous cell 
carcinoma 
Kazuya Kondo 
(University of 
Tokushima, Japan), 
I 
NCI-H520 
HTB-182 
Lung squamous cell 
carcinoma 
ATCC  I 
Calu-3 
HTB-55 
Lung adenocarcinoma ATCC  I 
NCI-H23 
CRL-5800 
Lung adenocarcinoma ATCC  I 
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A549 
CCL-185 
Lung adenocarcinoma ATCC  I,III,IV 
201T Lung adenocarcinoma Jay D. Hunt (Louisiana 
State University, New 
Orleans, LA), 
I 
M4A4-LM3 Breast cancer S.Goodison 
(University of Florida, 
FL)  
II 
Hs173we 
CRL- 
7834 
Human fibroblast Gerd Bauerschmitz, 
(University of 
Duesseldorf, Germany) 
III 
 
Fresh NSCLC primary tissue samples were collected after signed informed consent from 
patients diagnosed with advanced lung cancer at the Helsinki University Central Hospital. 
The study was approved by the hospital Ethics Committee (I). Bone marrow-derived 
human mesenchymal stem cells were isolated as described previously (Leskelä et al. 
2003). Adipose stem cells were obtained from human subcutaneous and intraperitoneal 
adipose tissues (II). 
2 Adenoviral vectors and replicating adenoviruses (I-IV) 
Table 4. Replication deficient and oncolytic adenoviruses used in this study 
Virus E1A Transgene Capsid 
modification 
Target 
receptor 
Source Study 
Adluc1 Deleted Luciferase - CAR (Dmitriev 
et al. 
1998).  
I,II, 
IV 
A5/3luc1 Deleted Luciferase Serotype 3 
knob 
Unknown 
and CD46 
(Kanerva 
et al. 
2002a).  
I, IV 
Ad5lucRGD Deleted Luciferase RGD motif 
in the HI 
αvβ 
integrins 
(Dmitriev 
et al. 
I,II, 
IV 
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loop and CAR 1998).  
Ad5(GL) Deleted Luciferase 
and GFP 
- CAR (Wu et al. 
2002).  
I, II, 
IV 
Ad5.pK7(GL) Deleted Luciferase 
and GFP 
7 polylysins 
in the C-
terminus 
Heparan 
sulfates 
and CAR 
(Wu et al. 
2002).  
I, II, 
IV 
Ad5.RGD.pK7(GL) Deleted Luciferase 
and GFP 
RGD motif 
in the HI 
loop, seven 
polylysins in 
the C-
terminus 
αvβ 
integrins, 
Heparan 
sulfates, 
CAR 
(Wu et al. 
2002).  
I, II 
Ad5.LacZ Deleted β -
galactosidase 
- CAR (Sarkar et 
al. 2005).  
I 
Ad5.pK7LacZ Deleted β -
galactosidase 
seven 
polylysins in 
the C-
terminus 
Heparan 
sulfates, 
CAR 
(Sarkar et 
al. 2005).  
II 
Ad5F/K21 Deleted β -
galactosidase 
21 polylysins 
in the C-
terminus 
Heparan 
sulfates, 
CAR 
(Sarkar et 
al. 2005).  
I 
Ad5Cox2Lluc Deleted Cox-2 
promoter 
luciferase 
- CAR This study 
unpublised 
data 
 
Ad5Cox2LlucUL Deleted Cox-2 
promoter 
Luciferase, 
3’UTR 
- CAR This study 
unpublised 
data 
 
Ad300wt 
(Ad5 wild-type) 
Intact - - CAR ATCC  I,II, 
III 
Ad5Δ24E3+ 24-bp 
deletion 
in CR2 
- - CAR (Suzuki et 
al. 2001).  
I, II, 
III 
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Ad5/3 -Δ24 24-bp 
deletion 
- Serotype 3 
knob 
Unknown, 
CD46 
(Kanerva 
et al. 
2003).  
I, II, 
III 
Ad5- Δ24RGD 24-bp 
deletion 
- RGD motif 
in the HI 
loop 
αvβ 
integrins, 
(Suzuki et 
al. 2001).  
I, II 
Ad5.pK7-Δ24 24-bp 
deletion 
- seven 
polylysins in 
the C-
terminus 
Heparan 
sulfates, 
(Ranki et 
al. 2007).  
I, II 
 
2.1 Construction of Cox-2 and 3’UTR element-expressing plasmids 
(III) 
In the plasmids pShuttleCox-2Lluc and pShuttleCox-2Lluc + 3’-UTR, the Cox-2L 
promoter (−1492/+59) was amplified by PCR from full-length Cox-2 containing 
pGL3/Cox-2  using forward primer 5’-AAAAGATCTGAGGTACCTGGT- 3’to place a 
BglII site at the 5’-end of Cox-2L and reverse primer 5’-
AAAAAGCTTCGCTGCTGAGGA-3’ to place a HindIII site at the 3’-end. A 603-bp long 
3’-UTR fragment from Cox-2 was amplified from pZeo/Luc3 + 3’-UTR using forward 
primer 5’-AAAATCTAGAAAGTCTAATGATC-3’ and reverse 5’- 
AAAATCTAGAAACTTTAAG-3’ to place XbaI at both ends. The Cox-2L promoter and 
3’-UTR were cloned into luciferase-containing plasmid pGL3basic. The final constructs: 
pShuttleCox-2Lluc and pShuttleCox-2Lluc + 3’-UTR were created by digesting 
pGL3Cox-2Lluc and pGL3Cox-2Lluc + 3’-UTR with KpnI and SalI and subcloning into 
pShuttle. pShuttleCMVluc and pShuttleCMVluc + 3’-UTR were also created: the 
luciferase gene and 3’-UTR were digested with KpnI and SalI from pGL3 basic and 
inserted into pShuttleCMV. All plasmids were purified by agarose gel electrophoresis. 
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Figure 6. Schematic presentation of the plasmids constructed in this study: 
pShuttleCox-2Lluc + 3’-UTR, pShuttleCox-2Lluc, pShuttleCMVluc + 3’-UTR and 
pShuttleCMVluc. 
Table 5. The plasmids used in this study 
Plasmid Description Source Used 
in 
pGL3basic pGL3 cloning vector Promega, Madison, WI III 
pGL3/Cox-2 pGL3 vector containing full-length 
Cox-2 
Ari Ristimäki, 
University of Helsinki, 
Finland 
III 
pZeo/Luc3 + 3’-UTR pZeo/Luc3 vector containing full-
length 3’UTR 
Ari Ristimäki III 
pShuttleCMV pShuttle vector containing CMV 
promoter 
Stratagene, La Jolla, CA III 
pShuttleCox-2Lluc pShuttle vector containing Cox-2L 
promoter driving luciferese 
This study III 
pShuttleCox-2Lluc + 
3’-UTR 
pShuttle vector containing Cox-2L 
promoter driving luciferese and 
3’UTR element 
This study III 
pShuttleCMVluc pShuttle vector containing CMV 
promoter driving luciferase 
This study III 
pShuttleCMVluc + 
3’-UTR 
pShuttle vector containing CMV 
promoter driving luciferase and 
3’UTR element 
This study III 
pAdEasyI E1/E3 deleted Ad5 genome This study unpublished 
data 
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2.2 Construction of non replicating adenoviruses 
Previously described plasmids pShuttleCox-2luc and pShuttleCox-2luc+3’UTR were 
digested with PmeI and homologous recombination was done with AdEasy I plasmid. 
Resulting plasmid was further digested with PacI and transfected with 293 cells. 
2.3 In vitro transfection of plasmids (III) 
1.5 × 105 cells were seeded into 12-well plates 17–20 h prior to transfection; 1 µg of each 
plasmid were transfected with Fugene 6 reagent (Roche, Basel, Switzerland) in a ratio of 
3:2 (Fugene 6/plasmid) following the manufacturer’s instructions. 
2.4 High titer production of viruses (I-IV) 
Replication-deficient and oncolytic adenoviruses were propagated in 293 and A549 cells, 
respectively. Viruses were purified by standard cesium chloride gradient techniques, and 
quality control was performed by PCR. Viral particles (vp) were determined by 
spectrophotometry, infectious units are expressed as the median tissue culture infective 
dose50 (TCID50) (Svensson et al.1999). 
3 In vitro studies 
3.1 Adenovirus-mediated gene transfer assays (I-III) 
Cells and tissue samples were infected with Ad5luc1, Ad5(GL), Ad5/3luc1, Ad5lucRGD, 
Ad5.pK7(GL), or Ad5.RGD.pK7(GL) for 30min and 1 hour respectively. Luciferase 
activity was determined 24 h postinfection with a luciferase assay system (Promega) 
according to the manufacturer’s protocol. Values are presented relative to syngeneic 
control viruses [Ad5luc1 and Ad5(GL)], which were assigned a value of 1. For 
immunohistochemistry, NCI-H460 cells were infected in chamber slides (Nunc, 
Naperville, IL). The next day, the cells were fixed with 10% formalin and permeabilized 
with 0.1% Tween 20/phosphate-buffered saline (PBS). Blocking was done with 1% bovine 
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serum albumin (BSA)/PBS for 30 min at room temperature. Antihexon was used as a 
primary antibody at a concentration of 1.5 mg/ml (LabFrontier, Seoul, Korea). Texas Red-
labeled secondary antibody (AbCAM, Cambridge, UK) was used at a concentration of 2 
mg/ml. Cells were stained with Hoechst dye (Oriola, Espoo, Finland), positive cells were 
counted, and fluorescence images obtained (Olympus Ix81, Biosystems, Munich, 
Germany). 
3.2 Determination of receptor expression by flow cytometry (II) 
For flow cytometric analysis, cells (2 x 105) were incubated for 20 min at 4°C with the 
following primary antibodies at a 1:200 dilution: anti-CAR (clone RmcB; Upstate Cell 
Signaling Solutions/ Millipore, Lake Placid, NY), anti-HSPG (clone F58-10E4; Seikagaku, 
Falmouth, MA), anti- αvβ3  integrin (clone LM609; Chemicon International/Millipore, 
Temecula, CA), anti-αvβ5 integrin (clone P1F6; Chemicon International/Millipore), or anti-
CD46 (clone E4.3; BD Biosciences, San Jose, CA). Cells were washed with fluorescence-
activated cell-sorting (FACS) buffer (phosphate buffered salin, PBS containing 2% serum) 
and incubated with a 1:200 dilution of phycoerythrin-labeled secondary antibody (goat 
anti-mouse polyclonal antibody; BD Biosciences) for 30 min at 4°C. Cells were washed 
with FACS buffer and analyzed by flow cytometry (FACSCalibur; BD Biosciences) to 
determine receptor expression levels. Unstained cells were used as a negative control. 
3.3 Cytotoxicity assay (I, II) 
The 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl-2H-
tetrazolium, inner salt [‘‘MTS’’] cell killing assay was performed, and viability was 
measured using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS 
assay; Promega), when at least one tested virus showed a cytotoxic effect in the two 
highest dilutions. In the crystal violet assay, cells were stained with crystal violet when the 
cytotoxic effect was as above. 
3.4 Semiquantitative polymerase chain reaction (III) 
Transfected Hs173We cells were incubated with Proteinase K (Qiagen, Valencia, CA, 
USA) at 37°C for 30 min. Proteinase K was then inactivated by 20 min of incubation at 
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95°C. Amplification (30, 40, and 60 cycles, annealing at 50°C) of a 77-bp DNA fragment 
was carried out by using primers that were positioned at the left end of the adenovirus 
genome, between the left inverted terminal repeat and the packaging signal. Upstream: 5’-
GCGACGGATGTGGCAAAAGT-3’(150-171bp) and downstream: 5’- 
CCTAAAACCGCGCGAAAA-3’ (211-228bp). 
 
3.5 Assessment of neutralizing antibody (NAb) titers (IV) 
A549 cells were seeded on 96-well plates and cultured overnight. Serum collected from the 
immunized ICR mice was incubated at 56°C for 60 min to inactivate the complement and 
then a 4-fold dilution series of serum was prepared in growth media without serum. 
Ad5(GL) (100 vp/cell) was mixed with diluted serum samples and incubated at room 
temperature on a rocker for 30 min, and the mix was added to cells in quadruplicates. Two 
hours later, the infection media was replaced by fresh growth media. After 48 h, luciferase 
expression was measured by FluorStar Optima luminometer (BMG LabTech, Offenburg, 
Germany) according to the manufacturer’s instructions. NAb titer was determined as the 
lowest degree of dilution that blocked gene transfer by more than 50%. 
3.6 Effect of NAbs on gene transfer (IV) 
Human NSCLC and normal lung tissue samples were homogenized and infected with 
Ad5(GL), Ad5/3luc1, and Ad5lucRGD (1000 vp / cell). Viruses were preincubated with 
(0, 1:512, and 1:4 dilutions) inactivated serum from Ad5(GL)-immunized mice at room 
temperature for 30 min before infection of tissue explants. A luciferase assay was 
performed in quadruplicate 24 h later by the using Luciferase Assay System (Promega). 
4 In vivo studies 
4.1 Mice and mice models used (I-IV) 
Female NMRI nude mice and immunocompetent ICR mice aged 3-4 weeks were obtained 
from Taconic (Ejby, Denmark) and quarantined for 2 weeks. All animal experiments were 
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approved by the Experimental Animal Committee of the University of Helsinki and the 
Provincial Government of Southern Finland. 
Subcutaneous models were created as follows: 1 × 106 293 and 5 × 105 A549 cells were 
injected into the flanks of mice. Tumors were allowed to develop for 30 days (293) or 14 
days (A549) to reach 5 mm in diameter. An orthotopic model of locally advanced lung 
cancer was created by injecting 2x106 cells (LNM35/EGFP) into the left lung of NMRI 
nude mice in a total volume of 200 ml using a syringe with a 27G needle. The orthotopic 
breast cancer model used in these studies has been described in more detail by Ranki et al. 
(Ranki et al. 2007b). Briefly, 2 x 106 M4A4-LM3 cells were injected into both the right 
and the left second lowest mammary fat pads. Tumors were allowed to develop until they 
reached a diameter of approximately 4 mm. Before injections, the mice were anesthetized 
with medetomidine (Domitor; Orion Pharma, Espoo, Finland) and ketamine (Ketalar; 
Pfizer, New York, NY) at 1:2. 
4.2 Biodistribution assay (I, IV) 
After tumors had developed (I) or 1 month after immunization (IV) 3x1010 vp were 
injected through the tail vein, and 48 h later, organs were harvested and frozen at -80°C. 
Organs were homogenized in Cell Culture Lysis Buffer (Promega), and luciferase 
expression was measured by using FluoStar Optima luminometer. 
4.3 Therapeutic assay (I, II) 
Advanced intrapulmonary disease was allowed to develop for 5 days and mice were then 
divided randomly into 5 groups (n=12 mice per group) (I) and (n=6-10 mice per group) 
(II). Viruses were injected into the tail vein (2x 1010 vp/mouse). Mice were treated on days 
5, 12, and 19 (I). Viruses injected along with MSC groups are as follows: either MSCs 
(7x105 cells/mouse, n=5), virus [1.4x 108 vp of Ad5.pK7(GL) ,7 x107 vp of Ad5.pK7- Δ24, 
n=10], MSCs infected with nonreplicating adenovirus [Ad5.pK7(GL) at 200 vp/cell, 
Ad5pK7LacZ at 100 vp/cell, 7x105 cells/mouse, n=6] or MSCs infected with oncolytic 
adenoviruses [Ad5.pK7(GL) at 200 vp/cell, Ad5.pK7-Δ24 at 100 vp/cell, 7x105 
cells/mouse, n=10] 7, 11, and 15 days after cancer cell inoculation. In the breast cancer 
model, tumors were measured in two dimensions with calibers and tumor volumes were 
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calculated according to the following formula: length x width2 x 0.5. The health of the 
mice was monitored daily, and mice were killed according to humane endpoint guidelines. 
4.4 In vivo transfection of plasmids and infection of viruses (III) 
Transfection was accomplished by using in vivo JetPei cationic polymer transfection 
reagent (Poly transfection, Illkirch, France) following the manufacturer’s protocol. Twenty 
four hours after transfection, 5 × 109 vp/tumor of Ad300wt in 100 µl was injected 
intratumorally. Tumors were collected and luciferase expression was analyzed as described 
previously in the biodistribution assay. 
 
4.5 Noninvasive in vivo imaging (I-III) 
Imaging was done by using the IVIS 100 Imaging System (Xenogen, Alameda, CA). 
Fluorescence emission was quantitated by determination of regions of interest, which were 
normalized to reference regions in the same image, but without tumor. When luciferase 
was imaged, luciferin substrate (4.5 mg/mouse) was injected intraperitoneally before 
bioluminescence imaging. 
4.6 Induction of NAbs (IV) 
ICR mice were immunized with viruses subcutaneously. Injection of 3x108 vp occured 
either once on day 0 or thrice on days 0, 3, and 6. Control animals were mock-immunized 
with serum-free media. On day 27, blood was collected from the hindlimb artery and 
allowed to clot, and serum was then separated by centrifugation and stored at -20°C for 
further experiments. 
4.7 Effect of NAbs on gene transfer (IV) 
Orthotopic tumors of advanced lung cancer were allowed to develop for 9 days before 
mice were injected with either viruses or serum at 1:512 or 1:4. Serum was pooled from 
ICR mice immunized once or thrice with Ad5(GL). Tumors were harvested 48 h later and 
luciferase assay was performed by FluorStar Optima. The data are protein-normalized (to 
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account for possible differences in tumor size) and presented relative to gene transfer 
obtained with no NAb. 
5 Statistics (I-IV) 
Pairwise comparisons were performed with Student’s t test, one-way analysis of variance 
(ANOVA) with Bonferroni’s post-hoc test, or ANOVA followed by Dunnett’s pairwise 
multiple comparison t-test. Survival data were analyzed with a log-rank test using SPSS 
software (version 11.5; SPSS Inc., Chicago, IL) or PROC LIFETEST (SAS version 9.1; 
SAS Institute, Cary, NC), using a Weibull distribution. Analysis of whether MSCs could 
improve the efficacy of oncolytic virus was performed with χ2 test (II). For comparison of 
tumor size, data were analyzed with a repeated measures growth model with PROC 
MIXED (SAS version 9.1). The effects of treatment group, time, and the interaction of 
treatment group and time were evaluated by F- tests (II). Analysis of TCID50 data was 
performed with an unpaired t- test with Welch’s correction (II). The results from Cox-2 
induction in vivo (III) were analysed with Multtest, version 9.1 (SAS Institute Inc., Cary, 
NC, USA). For all analyses, p<0.05 was deemed significant. 
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Results and discussion 
1 Modified adenoviruses show enhanced gene transfer to NSCLC 
cell lines, MSCs, and primary lung cancer tissues in vitro (I, II) 
One of the major concerns in adenoviral gene therapy is effective targeting since the 
primary receptor CAR exhibits variable expression on cancer cells (Bauerschmitz et al. 
2002; Kanerva et al. 2002b). We hypothesized that by using modified adenoviruses, we 
could enhance gene transfer to NSCLC cell lines, bone marrow, or fat tissue-derived 
human mesenchymal stem cells and lung cancer tissue samples fresh from patients. Ten 
NSCLC cell lines (Figure 1 in Study I) were infected with Ad5luc1, Ad5/3luc1, 
Ad5lucRGD, Ad5(GL), Ad5. pK7(GL), Ad5.pK7.RGD(GL), Ad5LacZ, and Ad5F/K21 
replication-deficient adenoviruses (Table 4). On the basis of our results, αvβ integrins and 
HSPG targeted viruses enhanced transduction up to 270- and 100-fold respectively in 
NSCLC cell lines. To examine whether the increased gene transfer was due to enhanced 
infection of the cells, we stained Ad5luc1-, and Ad5lucRGD-infected cells with antihexon 
antibody, which confirmed the hypothesis. In addition, we investigated gene transfer in 
primary NSCLC samples fresh from patients without any passaging, since geno- and 
phenotypes of clinical tumor specimens better resemble human tumor tissue. The results of 
four adenocarcinoma and two squamous cell carcinoma samples were in line with those of 
the NSCLC cell lines. The HSPG targeted Ad5pK7(GL) virus had up to 200-fold better 
gene transfer compared to the unmodified control virus (p<0.001) (Figure 2 in Study I). 
Both unmodified and genetically engineered MSCs have been widely used for various 
therapeutic purposes preclinically, and a number of studies have suggested an immune-
privileged nature for MSCs and their ability to avoid allogeneic rejection in human and 
animal models, broadening their potential for therapeutic use (Aggarwal and Pittenger 
2005; Chamberlain et al. 2004; Le Blanc et al. 2004). Antitumor activity of retrovirus 
vector-transduced MSC, producing IL-12, has been tested in a mouse melanoma 
model(Elzaouk et al. 2006), and MSC, transduced by a lentivirus vector to express human 
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OPG (osteoprotegerin) has been evaluated for the treatment of osteolysis in a myeloma 
bone disease model (Rabin et al. 2007). Modified MSCs loaded with adenoviruses have 
been successfully used preclinically as treatment alternatives for glioma, melanoma, and 
ovarian and breast cancers (Komarova et al. 2006; Stoff-Khalili et al. 2007b; Stoff-Khalili 
et al. 2007b; Studeny et al. 2002; Studeny et al. 2004b; Sonabend et al. 2008). 
Unfortunately, the infectivity of MSCs with serotype Ad5 viruses has been limited due to 
low expression of CAR (Conget & Minguell 2000; Mizuguchi et al. 2005; Studeny et al. 
2002).  
Based on our results, αvβ integrin- or HSPG-targeted adenoviruses increased gene transfer 
1100- and 11000-fold compared with the untargeted virus. To further confirm the data, we 
studied the expression levels of target receptors on MSCs by flow cytometry. Interestingly, 
the most expressed receptor was CD46, a proposed receptor of Ad3, although only slightly 
enhanced transduction of Ad3-targeted virus was seen (Figure 1 in Study II). These results 
are in accordance with data suggesting that CD46 is not the only receptor of Ad3 (Gaggar 
et al. 2003; Tuve et al. 2006b).  
2 Biodistribution of capsid-modified adenoviruses (I) 
The orthotopic murine model of advanced NSCLC created in this study may resemble the 
actual disease to some degree since it is very aggressive. The disease spreads from the 
primary tumor (located in the left lung with this model), to the mediastinal lymph nodes 
and later to the peritoneum. Replication-deficient viruses Ad5luc1, Ad5/3luc1, 
Ad5lucRGD, Ad5(GL), Ad5. pK7(GL), and Ad5.pK7.RGD(GL) were used to examine 
biodistribution after systemic delivery (Figure 4 in Study I). Although systemic delivery of 
viruses might be useful for treatment of disseminated diseases, there are many hurdles that 
a therapeutic vector faces in the bloodstream, such as the innate and adaptive immune 
response, potential adsorption to erythrocytes and thrombocytes and clearance by 
specialized cells in the liver and spleen (Baker et al. 2007; Mohr et al. 2008).  
 In our study, no statistical differences were observed between viruses. Although 
Ad5lucRGD and Ad5. pK7(GL) viruses showed moderately high gene delivery to the 
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lungs, kidneys, peritoneum, and ovaries, transduction to the tumor was also seen with the 
same viruses. The route of administration clearly also affects biodistribution since when 
administered systemically, adenovirus is exposed to many factors in the blood, such as 
coagulation factors IX and X and complement component C4-binding protein, which 
might determine the biodistribution of the virus (Shayakhmetov et al. 2005).  
3 Capsid-modified adenoviruses display improved cell killing 
efficacy in NSCLC in vitro and in vivo (I) 
Even though efficacy has been seen following local administration, nonreplicating 
adenoviral agents have not yet demonstrated systemic therapeutic efficacy in humans. To 
overcome this problem, oncolytic adenoviruses have been developed. An advantage gained 
by using replication-competent oncolytic viruses is the potential for local amplification 
within the tumor, following initial transduction of even a small number of cells. In theory, 
this oncolytic process continues as long as target cells for the virus persist. This process 
when rigorously controlled in the oncolytic adenovirus context could be of enormous 
therapeutic benefit. Oncolytic potency of replicating agents is mostly determined by the 
infectivity of the viruses (Douglas et al. 2001; Hemminki et al. 2001). Unsurprisingly, 
targeted oncolytic adenoviruses have shown impressive preclinical efficacy (Kanerva et al. 
2003; Ranki et al. 2007; Suzuki et al. 2001).  
We evaluated the potency of oncolytic adenoviruses harboring the same capsid 
modifications with a cell viability assay in vitro (Figure 3 in Study I). In contrast to 
previous results with replication-deficient viruses, Ad5/3-Δ24 (Table 4) showed the best 
cell killing efficacy in all cell lines tested. The finding could be explained by the structure 
of RGD-4C- or pK7-containing virions, which may lead to less rapid packaging (in 
comparison to gene delivery), perhaps due to the ‘‘sticky’’ nature of these moieties.  
In vivo, with the same panel of viruses in an orthotopic model of advanced lung cancer, the 
median survival times times were 19, 22, 23, 26, 26, and 26 days for no virus, Ad5luc1, 
Ad5/3-Δ24, Ad5-Δ24E3, Ad5.pK7-Δ24, and Ad5-Δ24RGD, respectively (Figure 5a in 
Study I). The therapeutic efficacy of Ad5-Δ24E3, Ad5.pK7-Δ24, and Ad5-Δ24RGD was 
57 
 
significantly enhanced compared with the untreated group (p<0.01). One mouse from the 
Ad5-Δ24RGD-treated group survived until the end of the experiment (93 days). Ad5/3-
Δ24 virus did not enhance survival of the mice, which might be partly explained by the 
biodistribution data. This finding is in accordance with data obtained from an orthotopic 
breast cancer model (Ranki et al. 2006). The route of administration clearly has an effect 
on the infectivity and oncolytic potency of Ad5/3-Δ24 since after intraperitoneal 
administration of Ad5/3-Δ24 in an orthotopic ovarian cancer model, survival was enhanced 
dramatically (Kanerva et al. 2003).  
4 MSCs target lungs in vivo (II) 
To use MSCs as carriers for adenoviruses, they should support the replication of oncolytic 
adenoviruses. To study replication and subsequent cytolysis, we infected in vitro passaged 
MSCs with a panel of oncolytic adenoviruses containing a 24 bp deletion in the E1A 
region and cell viability was analyzed by MTS assay (Figure 2 in Study II). The oncolysis 
correlated with the gene transfer of the viruses with the same targeting moieties (Figure 1 
in Study II). HSPG- and αvβ integrin-targeted oncolytic viruses showed significantly 
higher cytolysis rates in both adipose tissue- and bone marrow-derived cells. Ad5/3-Δ24 
virus also enhanced cell killing significantly compared with the unmodified virus (All p < 
0.001). The data revealed that cytolysis correlates with gene transfer. Previous finding of 
Komarova et al. showed that MSCs enable the replication of 5/3 targeted adenovirus with 
intact E1 (Komarova et al. 2006). Our viruses have a 24 bp deletion in E1A, allowing them 
to replicate in cells with a defective p16/Rb pathway. However, in vitro passaged MSCs 
feature phosphorylation of the Rb protein, which would be expected to allow replication of 
Δ24-type viruses, explaining the replication seen here (Heise et al. 2000a). We found no 
differences between the ability of adipose tissue- and bone marrow-derived cells to support 
the replication and allow release of active virions. 
Since MSCs have been shown to target tumors and act as a shield to pre-existing 
antibodies (Aggarwal & Pittenger 2005; Le Blanc et al. 2004; Mohr et al. 2008), these 
engineered stem cells might serve as therapeutic Trojan horses, therefore enhancing the 
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therapeutic efficacy in vivo compared with the virus alone. Recently, Gutova et al. 
provided evidence that urokinase plasminogen activator (uPA) and its receptor uPAR, 
involved in chemotaxis and cell guidance during normal development, are upregulated in 
invasive tumors and might augment neural and mesenchymal stem cell tropism (Gutova et 
al. 2008).  
In this study, we tested whether bone marrow-derived MSC could support viral replication 
and release in the context of orthotopic lung tumors. Mice received a single dose of 
intravenous oncolytic adenovirus (Ad5.pK7-Δ24) or MSCs infected either with replication-
deficient or oncolytic adenovirus. Luciferase-expressing virus was included in each group, 
which allowed us to use the noninvasive bioimaging system to follow the biodistribution of 
the virus (Figures 3 and 4 in Study II). Mice were imaged 15 min, and 3, 7, and 10 days 
after treatment. Initially, the luciferase signal was detected from the lungs of all MSC-
treated mice, but not in the virus-alone group because of a lack of sufficient time for 
luciferase production. On the third day, the oncolytic virus-loaded MSCs displayed a 
strong luciferase signal from the liver, suggesting that viruses had escaped from the MSCs 
and transduced the liver. A 60 time weaker luciferase signal was captured from the livers 
of mice treated with virus only. Replication-deficient virus with MSCs showed weak 
luciferase expression in the lungs. On the next imaging days, a weak luciferase signal was 
detected from the liver of both groups of MSC-treated mice, but not mice treated with 
virus alone (Figure 3 in Study II). In addition, the kinetic studies revealed that viral release 
from MSC carriers was relatively rapid because 24 h after MSC injection (i.e. 72 h after 
infection) some of the released virus was already detectable in the liver. Further, DiI-
labeled MSCs were injected intravenously into tumor-free, lung tumor- or breast tumor-
bearing mice to see more clearly whether the luciferase signal was from the lungs or from 
the tumor. A strong fluorescence signal was obtained symmetrically from both lungs, 
suggesting accumulation preferentially in the lungs instead of specificity for tumors. No 
MSCs were found in breast tumors. In conclusion, we were able to demonstrate that MSCs 
loaded with oncolytic viruses homed to lungs of mice bearing orthotopic tumors. In 
contrast to previous reports, no tumor tropism was seen (Komarova et al. 2006; Studeny et 
al. 2004b).  
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5 Oncolytic adenoviruses and MSCs loaded with oncolytic 
adenoviruses show therapeutic efficacy in an orthotopic murine 
model of advanced lung and breast cancers (II) 
Therapeutic efficacy of MSCs packed with oncolytic adenoviruses was investigated in 
orthotopic models of advanced lung and breast cancers (Figure 6 in Study II). Mice were 
treated with virus only (Ad5.pK7-Δ24),MSC only, MSC + oncolytic adenovirus 
(Ad5.pK7-Δ24), MSC + replication-deficient adenovirus (Ad5pK7LacZ) and median 
survival times were 23, 25, 27, and 28 days, respectively, for lung tumor-bearing mice, and 
survival was significantly enhanced (p=0.0031) with MSC loaded with oncolytic 
adenovirus. In an advanced breast cancer model the MSCs with oncolytic adenoviruses 
inhibited tumor growth significantly (p<0.001) compared with control mice. These results 
suggest that despite MSCs lacking a specific tumor-targeting capacity, they were able to 
release the virus for subsequent transduction of tumors, and enhanced therapeutic efficacy 
was seen. 
6 In vivo monitoring of oncolytic adenoviruses (I, II) 
Imaging has become an indispensable tool in cancer research, clinical trials, and medical 
practice. Imaging systems can be grouped by the energy used to derive visual information 
(X-rays, positrons, photons, or sound waves) (Groot-Wassink et al. 2004), the spatial 
resolution attained (macroscopic, mesoscopic, or microscopic), or the type of information 
obtained (anatomical, physiological, cellular, or molecular). In the context of adenoviral 
gene therapy, longitudinal monitoring of tumor burden and viral spreading has advantages 
over survival alone. 
In this study, fluorescence and bioluminescence imaging were used to follow up tumor 
burden and the spreading of adenoviruses in vivo. Overall, imaging data correlated well 
with date achieved from biodistribution and survival experiments. The fluorescence 
imaging used in Study I (Figure 6) even revealed individual variation in mice treated with 
oncolytic adenoviruses. Mice treated with Ad5-Δ24RGD were grouped according to 
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response. Some mice had progressive disease, the disease stabilized in others, and others 
had dramatic responses. In addition, imaging allowed us to track MSCs loaded with the 
adenoviruses more precisely in mice (Figures 3-5 in this Study II) 
7 Cox-2 and CMV promoter are induced following adenovirus 
infection, but the Cox-2 3’UTR element can retain specificity in 
vitro and in vivo (III) 
Achievement of oncolytic replication in tumor cells while avoiding nonspecific replication 
in normal tissues remains a major challenge in oncolytic gene therapy. In this regard, the 
elucidation of the critical pathways involved in the adenoviral infectious cycle has 
provided the basis for multiple levels of control to achieve the goal of selective replication. 
Tumor-specific promoters are at the foundation of transcriptional targeting, and Cox-2 
promoter has been among the more popular candidates (Bauerschmitz et al. 2006; Casado 
et al. 2001; Hirschowitz et al. 2002; Liang et al. 2004; Nettelbeck et al. 2003; Yamamoto 
et al. 2001; Yamamoto et al. 2003; Kanerva et al. 2005).  
However, the physiological function of Cox-2 as an enzyme expressed upon inflammation, 
infection and injury as well as in tumors is very well established (Kujubu et al. 1991; 
Smith 1992; Turini & DuBois 2002). The Ras/MAPK group, one of the common pathways 
to control the cell cycle, is mutated in most cancers. Cox-2 expression is both upregulated 
transcriptionally and downregulated posttranscriptionally by the RAS/p38/MAPK pathway 
(Lasa et al. 2000). Downregulation is in partly through AU-rich elements within the 3’-
UTR, and their physiological function is to rapidly downregulate Cox- 2 mediated 
transcripts, when the threat (e.g. infection) has passed. Naturally, cancer cells have learned 
to take advantage of this mechanism and Cox-2 is stabilized through defected Ras pathway 
in tumor cells (Cok & Morrison 2001; Dean et al. 1999; Dixon et al. 2000).  
In this study, we hypothesized that Cox-2 promoter is induced by adenoviral infection, but 
the specificity could be regained by utilization of 3’UTR elements. First, nonmalignant 
293 cells were transfected with pShuttleCox2Lluc plasmid featuring Cox-2L promoter 
driving luciferase, and the cells were then infected with a wild-type Ad5, a selectively 
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oncolytic adenovirus Ad5-Δ24E3, or an E1-deleted adenovirus (Ad5LacZ) (Figure 2 A-C 
in Study III). Infection with a wild-type adenovirus or a conditionally replicating virus 
resulted in significant Cox-2 induction (p<0.05 and p<0.01, respectively). Replication-
deficient adenovirus also induced Cox-2 in these E1-containing cells, which allows 
replication of E1-deleted viruses (p<0.05). Further, we sought to investigate whether this 
Cox-2 induction is a cell type-specific phenomenon, and human fibroblasts were 
transfected and infected as previously, except that Ad5/3-Δ24 virus was used instead of 
Ad300wt. Induction of the promoter seemed to be related to replication or E1 proteins 
since Cox-2 was induced by replication-competent adenoviruses but not by replication-
deficient Ad5LacZ virus (Figure 3 in Study III). In addition, Ad5/3-Δ24 virus, which 
replicates more efficiently in most cell types, also (Bauerschmitz et al. 2006; Kanerva et 
al. 2003). induced higher Cox-2 levels (Figures 3 and 4 in Study III). 
When the same cell lines were transfected with a plasmid containing 3’UTR element after 
the luciferase gene (pShuttleCox2Lluc+3’UTR) and infected with the same viruses, the 
3’UTR element was able to abrogate induced Cox-2 expression in nonmalignant cells, but 
had little impact on malignant cells (Figures 2–4 in Study III). Interestingly, our control 
plasmids with CMV promoter with or without 3’UTR showed that CMV promoter is also 
induced by adenoviral infection to a similar degree as the Cox-2 promoter in all cell lines, 
and the UTR element also had a similar activity on the CMV promoter (Figures 2-4, panels 
D-F).  
The induction of Cox-2 and CMV promoters was also studied in vivo. Subcutaneous 293 or 
A549 tumors were allowed to develop 30 and 14 days, respectively, and were then 
transfected with plasmids followed by intratumoral injection of wild-type adenovirus the 
next day. To investigate the induction, bioluminescence was imaged 15 min and 24 h after 
infection. Interestingly, there was a 4.3-fold induction in Cox-2 expression only 15 min 
after infection and this persisted to the next imaging. 3’UTR did not have time to affect 
expression during the first round of imaging, but 24 h later luciferase expressed by the 
Cox-2–3’UTR complex in infected cells decreased from 55 039 to 51 716, whereas in 
uninfected cells the luciferase continued to increase as expected (from 4339 to 14 519). 
The destabilization signal therefore appeared to work as predicted. However, there were 
variations typical of in vivo luciferase imaging and the complexities associated with in vivo 
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plasmid transfection followed by intratumoral infection, and therefore, no statistically 
significant differences between groups could be seen. After the second round of imaging, 
the tumors were excised and the amount of luciferase protein was analyzed. The results 
were in line with imaging data. Adenovirus infection induced expression of the Cox-2 and 
CMV promoters in both nonmalignant and malignant cells, and the 3’UTR element had an 
effect on the induction in 293 cells (Figures 5 and 6 in Study III). 
In contrast to the promising data achieved from Cox-2 and 3’UTR expressing plasmids, the 
effect of the 3’UTR element was not powerful enough to downregulate the expression 
Cox-2 promoter driven luciferase in the context of replication deficient adenoviruses in 
human fibroblasts (Figure 5, unpublished data). 
 
Figure 5. Replication deficient adenovirus expressing 603bp long 3’UTR element has 
a minor impact on downregulation the expression of luciferase. Human fibroblasts 
were infected with Ad5Cox2Lluc and Ad5Cox2LlucUL with, 40, 200, 1000 and 5000 
vp/cell. Luciferase was imaged 24h after infection. 
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8 Switching the adenoviral fiber retains viral gene transfer in the 
presence of NAbs (IV) 
The use of adenoviral vectors in gene therapy has been hampered by significant problems 
with attendant host immune responses that limit their safety and efficacy in vivo (Wilson 
1996). Adenoviral vectors can effectively elicit the innate immune response immediately 
after infection, leading to the secretion of proinflammatory cytokines and chemokines in 
mice, humans, and nonhuman primates and that might damage healthy tissue (Raper et al. 
2003; Schnell et al. 2001; Zhang et al. 2001). Problems particularly may arise after 
systemic delivery or upon readministration of adenoviruses. Recently, Zhu et al. described 
adenoviruses to elicit an innate immune response through the TLR9-MyD88 pathway in 
plasmacytoid DCs (pDCs) and a TLR-independent pathway in non-pDCs, leading to 
production of mainly type I IFNs (Zhu et al. 2007a).  
We investigated whether the changes in the adenoviral fiber could allow the virus to 
escape from NAbs. To test the gene transfer of Ad5 in the presence of NAbs, 
immunocompetent mice were immunized with capsid-modified replication-deficient 
adenoviruses (see Table 6), and the inhibitory effect on Ad5(GL) gene transfer efficacy 
was analyzed. We used a single immunization to model a low level of NAb and a triple 
immunization to simulate a high NAb titer. Triple immunization with Ad5(GL) resulted in 
complete blocking of in vitro gene transfer by Ad5(GL). By contrast, after triple 
immunization with Ad5/3luc1 or Ad5pK7(GL), Ad5(GL) was not blocked. Anti-
Ad5lucRGD NAbs marginally inhibited Ad5(GL) gene transfer (Table 2 in Study IV). 
These are consistent with previous results showing an ability of RGD or 5/3 modifications 
of the Ad5 fiber to avoid pre-existing anti-Ad5 NAb present in human serum or ascites 
(Hemminki et al. 2001; Kanerva et al. 2003). Immunized mice were injected intravenously 
with Ad5(GL), and organs were harvested for luciferase measurement (Table 6). A single 
immunization with Ad5(GL) reduced subsequent gene transfer with Ad5(GL) to the liver 
(p<0.001), heart (p<0.001), spleen (p<0.05), pancreas (p<0.05), and kidney (p<0.01), in 
contrast to a single immunization with the other viruses, which did not significantly inhibit 
gene transfer of Ad5(GL) in most organs. However, triple immunization did produce a 
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stronger antibody response, and NAbs to capsid-modified adenoviruses started to reduce 
gene transfer of Ad5(GL). Liver transduction was decreased more than 1000-fold with 
Ad5(GL) compared with a single immunization with the same virus (Figures 2 and 3 in 
Study IV). Although a degree of cross-blocking was seen for all viruses, Ad5/3luc was 
affected the least, probably due to the complete knob-swap in the fiber, suggesting that 
anti-fiber knob NAbs might be most relevant. 
Table 6. Induction of neutralizing antibodies and determination of their effect on 
gene transfer in immune-competent mice. 
Abbreviations: i.v., intravenous injection (3 x 1010 vp); NAb, determination of neutralizing antibody 
titer from serum; s.c., subcutaneous immunization (3 x 108 vp); vp, viral particle 
 
The effect on gene transfer in the presence NAbs was also evaluated in vivo. Mice bearing 
orthotopic tumors of advanced lung cancer were injected intravenously with Ad5(GL), 
Ad5/3luc1, Ad5lucRGD, or Ad5pK7(GL) or with the same viruses preincubated with 
serum collected from Ad5(GL)-immunized mice. A low titer of anti-Ad5 NAb did not 
block intravenous Ad5(GL), but a high titer almost completely prevented gene transfer. 
Regardless of anti-Ad5 NAb titer, effective gene delivery was achieved with Ad5lucRGD, 
Ad5/3luc1, and Ad5pK7(GL) (Figure 4 in Study IV). 
Group I II III IV V VI VII VIII IX X 
DAY           
0 (s.c.) Ad5(GL) Ad5(GL) Ad5/3luc1 Ad5/3luc1 Ad5lucRG
D 
Ad5lucRG
D 
Ad5pK7(
GL) 
Ad5pK7(
GL) 
mock mock 
3 (s.c.)  Ad5(GL)  Ad5/3luc1  Ad5lucRG
D 
 Ad5pK7(
GL) 
 mock 
6 (s.c.)  Ad5(GL)  Ad5/3luc1  Ad5lucRG
D 
 Ad5pK7(
GL) 
 mock 
27 Nab NAb NAb NAb NAb NAb NAb NAb NAb NAb 
28 (i.v.) Ad5(GL) Ad5(GL) Ad5(GL) Ad5(GL) Ad5(GL) Ad5(GL) Ad5(GL) Ad5(GL) Ad5(GL) Ad5(GL) 
29 organs & 
serum 
organs & 
serum 
organs organs organs organs organs organs organs organs 
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Two human squamous cell carcinomas, one adenocarcinoma, and one non-malignant lung 
tissue specimen were obtained fresh from patients and infected with viruses preincubated 
with serum collected from Ad5(GL)-immunized mice. Ad5(GL) was completely blocked 
by a high NAb titer, whereas Ad5/3luc1 and Ad5pK7(GL) continued to allow gene 
transfer. Both Ad5/3luc1 and Ad5pK7(GL) showed enhanced gene delivery compared with 
the Ad5(GL) in the presence of low or high NAb. Intriguingly, anti-Ad5 NAb blocked 
gene transfer by capsid-modified viruses to normal human lung explants much more than 
to tumor explants (Figures 5 and 6 in Study IV). This might be explained by the fiber 
knob-independent mechanisms proposed to be important in systemic biodistribution of 
mice and primates (Bayo-Puxan et al. 2006; Smith et al. 2003a; Smith et al. 2003b).  
In conclusion, our data suggest that relative escape from the NAbs is achieved after 
systemic delivery using capsid-modified adenoviruses. 
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Summary and conclusions  
The overall aim of this study was to obtain information on adenovirus tropism towards 
NSCLC cells and to enhance therapeutic outcome with oncolytic adenoviruses. To further 
improve the specificity, we sought to determine whether the Cox-2 promoter is induced by 
adenovirus infection and whether selectivity could be regained by 3’UTR elements. 
Finally, we tested whether switching the adenovirus fiber can retain gene delivery in the 
presence of NAbs. 
HSPG- and αvβ integrin-targeted viruses displayed enhanced gene transfer to NSCLC cells 
in vitro and in vivo. Respective oncolytic viruses showed effective cell killing and this 
translated into a therapeutic benefit in a highly aggressive orthotopic model of large-cell 
NSCLC. Combination therapies with radio- or chemotherapy and arming oncolytic viruses 
with immunostimulatory or cytotoxic transgenes could lead to an even better therapeutic 
outcome.  
Most importantly, the data laid the foundation for clinical testing of these viruses in 
patients with NSCLC refractory to current treatments.The use of cells as oncolytic virus 
delivery vehicles offers a number of potential advantages. One lies in the tumor-homing 
capacity of certain cells. A second advantage is that carrier cells can be engineered to 
express a set of transgenes exceeding the cloning capacity of the viral vector considered, 
thereby actiing as local virus factories allowing high amplification of the inoculated virus. 
Finally, oncolytic viruses harbored by carrier cells remain at least partly protected from 
inactivation by the host until released at their destination.  
MSCs possess multilineage properties making them useful for a number of potential 
therapeutic applications, and they have suggested targeting many different cancers. 
Infectivity of MSCs could be enhanced by using capsid-modified adenoviruses. In 
addition, MSCs were able to support the replication and viral release of oncolytic 
adenoviruses harboring a 24-bp deletion in the E1A region both in vitro and in vivo. 
Further, MSCs loaded with oncolytic adenoviruses prolonged the survival of mice with 
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advanced lung cancer and showed enhanced antitumor efficacy with breast cancer tumors 
after systemic delivery. These data suggest that MSCs could improve the bioavailability of 
adenoviruses in the context of advanced and aggressive disease. 
Viruses are known to induce Cox-2 (not previously known for adenovirus), but the 
mechanisms behind this phenomenon are poorly understood. It is unclear whether Cox-2 
induction occurs due to a protective antiviral response initiated by human cells, or whether 
viruses can also actively promote Cox-2 induction for their own purposes. Our results 
suggest that both Cox-2 and CMV promoters are induced by adenoviral infection, but 
selectivity could be rescued by the 3’UTR element of the Cox-2. It would be interesting to 
study the activity of these elements in the context of oncolytic adenoviruses, and further, to 
determine whether other tumor specific promoters could be controlled by these elements. 
Another approach to enhance the efficacy of adenoviral gene therapy is to reduce the effect 
of Nabs. Our data proposed that minor changes in adenovirus fiber can allow the virus to 
escape from pre-existing Nabs, and therefore, more effective systemic readministration 
could be achieved. It might be even more beneficial to use viruses from different 
serotypes, or viruses pseudotyped with the entire fiber (instead of just the knob) or hexon 
might yield further advances. It would also be interesting to study MSCs in the context of 
NAbs. 
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